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III ABSTRACT 
The emergence of opportunistic nosocomial bacteria Acinetobacter baumannii, which causes 
infections in critically ill patients with compromised immune systems, is one of the most 
clinically challenging pathogens to treat effectively.  
Most nosocomial pathogens grow as monoculture or poly-species biofilms in infections and 
the biofilm mode of existence for A. baumannii may almost certainly contribute to its 
increased multi-drug resistant (MDR), although resistance can also be attributed to many 
contributing factors including overuse and misuse of antibiotics in hospitals and the 
community.  
In vitro methods for studying microbial biofilms have developed to include the CDC biofilm 
reactor, Flow cell devices and MBEC™ but in vivo biofilm model development has been very 
limited. Few simple animal models are available which reflect either the biofilm nature of 
growth of pathogens or the treatment of infection influenced by biofilm development in vivo.  
Biofilm formation is a critical virulence and defence strategy for bacteria, the present study 
focuses on working towards establishing a biofilm generated in-vivo model to assess the 
efficacy of antimicrobials against A. baumannii infections. 
The present study looks at the effects of broad spectrum antibiotics (BSA) and colistin 
combinations against lethal planktonic or biofilm A. baumannii infections with a pre-clinical 
insect model, Galleria mellonella (Greater wax moth larvae). The work shows colistin to be an 
important synergist both in vitro and in a simple in vivo model. This work is the first to describe 
a model biofilm associated infection in G. mellonella.    
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1 INTRODUCTION 
Emerging as one of the most clinically problematic pathogens due to its resistance to multiple 
antibiotics, Acinetobacter baumannii is increasingly becoming one of the most studied species 
of the genus Acinetobacter. Acinetobacter bacteria are typically opportunistic pathogens, 
posing as a significant threat to critically ill hospitalised patients with an already compromised 
immune system. A. baumannii infections have also been reported to have been identified in 
individuals with open wounds, or compromised individuals with medical invasive devices such 
as urinary catheters. At present 17 species of the genus Acinetobacter are recognised, with A. 
baumannii being the most commonly isolated species from human specimens. The organism 
is an aerobic Gram-negative bacterium, recovered from soil, water, and animals1-7.  
 
Understanding how prevalent the natural habitats of nosocomial bacteria such as A. 
baumannii enables a greater understanding of the infection characteristics of these bacteria. 
Most nosocomial pathogens grow as monoculture or poly-species biofilms in infections8. The 
biofilm mode of existence for A. baumannii may almost certainly contribute to its increased 
multi-drug resistant (MDR), although resistance can also be attributed to many contributing 
factors including overuse and misuse of antibiotics in hospitals and the community9, 10.  
 
In vitro methods for studying microbial biofilms have developed to include the CDC biofilm 
reactor, Flow cell devices and MBEC™ (formerly known as Calgary peg) but in vivo biofilm 
model development has been very limited. Few simple animal models are available which 
reflect either the biofilm nature of growth of pathogens or the treatment of infection 
influenced by biofilm development in vivo11.  Biofilm formation is a critical virulence and 
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defence strategy for bacteria and the resent study focuses on establishing a biofilm generated 
in-vivo model to assess the efficacy of antimicrobials against A. baumannii infections in a more 
realistic way than previously described. 
 
Colistin monotherapy has been a last resort in clinical practice, when the use of Beta-lactam, 
aminoglycoside or quinolone antibiotics are ineffective, to counter serious infection with A. 
baumannii but more recently, resistance has emerged rapidly; groups have also reported the 
emergence of colistin hetero-resistance after patients had prolonged exposure to colistin12, 
13.  
 
Entirely new agents against A.baumannii are under evaluation and development but are 
unlikely to be available for clinical use for many years and in the meantime clinicians have 
considered many ad-hoc combinations of existing licensed drugs in the hope that they will act 
synergistically14, 15.  Effective combination therapy with low colistin doses has been suggested 
as the best strategy to counter colistin-resistant A. baumannii13, 16.   
 
Research groups recently developed robust alternatives to traditional mammalian models of 
infection to provide evidence of in vivo efficacy due to concerns about practicality, cost and 
ethical issues17. Invertebrate models have been under consideration as an inexpensive and 
laboratory based alternatives18-24. This study investigates the use of the Galleria mellonella 
invertebrate model to evaluate the effects of mono- and combination therapy against biofilm 
associated infections. 
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2 LITERATURE REVIEW 
2.1  ACINETOBACTER BAUMANNII 
 
A. baumannii had been established as one of the most clinically problematic nosocomial 
pathogens due to its resistance to multiple antibiotics (Multidrug-resistant, MDR), remarkable 
ability to up regulate and/or acquire resistant mechanisms and ability survive for prolonged 
periods throughout hospital environments; A. baumannii is increasingly becoming one of the 
most studied species of the genus Acinetobacter5.  
 
A. baumannii is an aerobic Gram negative, catalase positive, oxidase negative, nonmotile, 
nonfermenting bacterium. They are cocco-bacilli that are difficult to destain which can lead 
to their misidentification as either Gram negative or Gram positive1, 5, 25.  
 
2.1.1 Natural history  and Epidemiology 
2.1.1.1  Natural Habitats  
Understanding how prevalent the natural habitat of A. baumannii is can provide a greater 
understanding of the infection characteristics of these bacteria however due to misreporting 
in earlier studies there has been confusion about A. baumannii and its natural habitat. 
Giamarellou et al.1 stated that A. baumannii is everywhere in nature, which is certainly true 
in the case of certain members of the genus Acinetobacter. These species are considered 
ubiquitous organisms that are readily sourced from virtually all samples of soil or the surfaces 
of water5. However this is a misconception for A. baumannii species and in a review carried 
out by Peleg et al.5 A. baumannii was rarely found to be on the skin or faeces of patients with 
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uncompromised immune systems. Moreover although it had been found in soil samples from 
Hong Kong and on vegetables from the UK, A. baumannii does not appear to be an 
environmental organism5.  In conclusion, A. baumannii should not be considered ubiquitous, 
however the lack of data available from the report did mean that the natural habitats of A. 
baumannii were not able to be accurately defined and remain this way5, 26. 
 
2.1.1.2 Epidemiology 
In Europe transitions of the epidemic strains of A. baumannii have been observed in hospitals 
with the mostly likely cause of transfer via colonised patients. The spread of Multidrug-
resitant (MDR) A. baumannii was found not to just be confined to hospitals within a city but 
also on a national scale5. From late 2003 to 2005, The Public Health England (formerly Health 
Protection Agency) national reference laboratory received approximately 1600 isolates of 
Acinetobacter spp. including carbapenem-resistant A. baumannii species. Representative of 
these clones were obtained from 48 hospitals in total in southeast England, indicating the 
widespread of the clones across counties27.   
Most concerning is the increased reports of intercontinental spread of A. baumannii has also 
been described between Europe and other countries as a consequence of colonised patients 
being transferred for treatment via air travel5 28. The ability of A. baumannii to survive in the 
environment, together with an enhanced capacity to acquire antibiotic resistance 
determinants, may have contributed to the bacterium’s ability for successful dissemination 
and persistence in hospitals across the world26. 
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2.1.2 Source of infection 
Over the past 20 years the significant role of A. baumannii in the colonisation and infection of 
immune compromised patients admitted to hospital has increased. As a pathogen, A. 
baumannii specifically targets moist tissues such as mucous membranes or areas of the skin 
that are exposed through accident or injury26. The bacterium has been implicated in a variety 
of nosocomial infections including bacteraemia, urinary tract infections, secondary meningitis 
and, in particular, ventilator-associated pneumonia and in the invasion of burn wounds2, 5. 
 
A. baumannii is an opportunistic pathogen generally effecting individual patients with an 
already compromised immune system; A. baumannii is usually non-pathogenic in healthy 
individuals. However Jones et al.3, who investigated casualties with uncompromised immune 
systems from Iraq, found A. baumannii to be one of the major causes of bacterial wound 
infection. This suggests that A. baumannii is not only an opportunistic pathogen in individuals 
with a compromised immune system, but also those who have had medical invasive devices 
fitted, such as catheters or open wounds.  
 
In addition to this, work by Zanetti et al.7 also found that A. baumannii infection is not only 
transferred from patient to patient, but also from the environment where colonised patients 
had been isolated for treatment. Zanetti et al.7 reported on the case of a burns victim who 
had contracted an A. baumannii infection whilst being transferred to hospital. Two other 
patients from the same ward were also infected, however environmental swabs samples of 
the ward tested negative for A. baumannii. Six months later, 6 patients contracted the same 
strain of A. baumannii. Environmental swab samples taken tested positive for A. baumannii 
13 
 
showing wide spread environmental contamination is possible through patient to patient 
contact.  
 
2.1.3 Mechanisms of resistance 
A. baumannii is defined as multidrug resistant to nearly all available antibiotics, including 
beta-lactams, fluoroquinolones, tetracyclines and aminoglycosides16. The wide array of 
antimicrobial resistant mechanisms that have been described for A. baumannii is extensive5. 
 
2.1.3.1 Intrinsic resistance 
Intrinsic resistance is the innate ability of a bacterial species to resist the activity of particular 
antimicrobial agents through its structural or functional characteristics29. One reason for 
Gram-negative resistance to a large number of antibiotics is a result of the effective 
permeability barrier of their outer membrane. The outer membrane is impermeable to 
macromolecules and allows only limited diffusion of hydrophobic substances through its 
lipopolysaccharide (LPS)-covered surface30.    
 
2.1.3.2 Acquired resistance 
The ability for A. baumannii to become resistant to such a large number of antibiotics has 
been attributed to the bacterium’s ability to accumulate antibiotic resistant mechanisms 
some of which include, degradation enzymes against beta-lactam antibiotics, modification 
enzymes against aminoglycosides, altered binding sites for quinolones and changes in the 
outer membrane proteins5, 26. The ease at which A. baumannii can acquire and incorporate 
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genetic elements and the low permeability of the outer membrane to certain antibiotics tends 
to explain how A. baumannii has become universally a multidrug-resistant bacterium1, 4, 31, 32.  
 
2.1.4 Biofilms  
In nature, is well accepted that bacteria do not exist as planktonic (free-cell) cultures but 
predominantly exist by attaching to and growing upon living and inanimate surfaces33. Such 
structures are known as biofilms, and defined by Costerton et al.34 as bacterial populations 
encapsulated within a matrix of secreted exopolymeric substances (EPS) that are attached 
to a surface adherent to each other and/or surfaces or interfaces. The matrix of the biofilm 
provides protection of the bacterial cells to physical and environmental stressors, it also 
provides an environment within which the cells can communicate with each other, 
transferring genetic information. Most biofilms rarely exist as mono-species, rather as 
polymicrobial multicellular communities encased within the EPS matrix35-38. The 
predisposition of biofilms to exist as functioning multicellular communities communicating 
between each other via cell to cell signalling known as quorum sensing, makes bacterial cells 
similar to other types of living cells which are capable of unicellular existence, yet preferably 
reside within multicellular communities35. 
 
Biofilms have a great significance for public health as biofilm-associated microorganisms 
have been shown to be implicated in numerous debilitating, and often chronic diseases; 
including cystic fibrosis, orthodontic diseases, sinusitis and some forms of heart disease39-41. 
They exhibit dramatically decreased susceptibility to antimicrobial agents and this 
susceptibility may be intrinsic or acquired33.  
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2.1.4.1 Biofilm associated A. baumannii 
The biofilm mode of existence for A. baumannii can be attributed to the bacterium’s 
increased MDR, although resistance can also be attributed to many contributing factors 
including overuse and misuse of antibiotics in hospitals and the community9, 10.  
 
A recent review into the evidence of biofilms in wounds by Percival et al.42 highlighted 
studies that detailed biofilms in wounds, the effect they have on infection and wound 
healing. The studies featured in the review provided evidence that biofilms reside within the 
chronic wound and most interestingly represent an important mechanism underlying the 
observed, delayed healing and infection. In a letter to the editor, Rodriguez-bano43 detailed 
a study his group had undertaken exploring the biofilm forming capabilities of A. baumannii. 
In their study they found that certain strains of A. baumannii were capable of forming 
biofilms and these strains had played a role in the pathogenesis of some device-associated 
A. baumannii infections. 
 
2.2 REVIVING OLD ANTIBIOTICS 
It is the emergence of MDR nosocomial bacteria to which there is a concerning void of 
discovery for new antimicrobials, that is with new target sites, which has led to the revival of 
antibiotics whose use was once restricted based on the discovery of less toxic antibiotics. The 
present study, focuses on the use of antibiotics from the polymyxin family, and in particular 
the polycationic antibiotic, Colistin, also known as polymyxin E. 
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2.2.1  Polymyxin antibiotics  
Polymyxins were first available in the commercial markets the 1950s but their usage was 
abandoned due to the high risks of renal failure, a well-known side effect of the Polymyxins 
family of drugs4, 5, 31. The family of Polymyxins were first discovered over 50 years ago then 
abandoned soon after due to their toxicity, they were never subjected to the rigorous 
development modern drugs have undergone31.  
 
The Polymyxin family consist of five chemically different antibiotics, A to E, of which two, 
Polymyxin B and E (colistin) are currently available on the clinical market; all polymyxins have 
a similar antibacterial spectrum and mode of action2, 31, 44. Colistin and Polymyxin B have been 
shown to be active against Gram-negative bacteria, including A. baumannii 15. Colistin and 
Polymyxin B comprise basic polypeptide antibiotics with a side chain terminated by 
characteristic fatty acids, see figure 2.1.  
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Figure 2.1: Chemical structure of Polymyxin B and E (colistin) showing the characteristic 
fatty acid tail. Source: Biswas et al. 31. 
 
Colistin is administered as an inactive pro-drug, colistin methanesulphonate (CMS), which is 
converted in vivo to its active form, colistin. Colistin (and Polymyxin B) act by displacing 
magnesium and calcium (ions that normally stabilize the lipopolysaccharide molecules) from 
the negatively charged lipopolysaccharide in the bacterial cell membrane. This leads to a loss 
of integrity of the membrane and an increase in the permeability of the cell envelope, leakage 
of cell contents, and subsequently, cell death45. The initial mode of action of colistin and 
polymyxin B is one that is regarded as non-lethal, at low doses, both peptide compounds have 
been shown to disrupt and permeabilise the outer membrane without causing the death of 
the cell45-47. The bactericidal action of the polymyxins, happens after initial drug molecules 
bind to and disrupt the outer and inner membrane of the cell, ‘free’ peptide  molecules then 
cause the leakage of the cytoplasmic contents of the cell 31, 48, 49, Figure 2.2. 
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Figure 2.2: Schematic diagram of the mode of action of colistin. Source: Biswas et al.31. 
 
Recent years has seen the increased use of colistin as a last resort antibiotic for MDR Gram-
negative associated infections. Figure 2.3 was taken from a review by Biswas et al.31 
graphically representing the number of citations collected from PubMed from dates ranging 
from 1960 to the middle of 2011. The graph shows the trend in popularity for the use of 
colistin in research, which has increased in the 21st Century. The graph also shows the increase 
of colistin resistance over the same time period. As the number of publications increase, so 
do the reports of colistin resistance.  
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It is also noteworthy that there has been an increase in heteroresistance of colistin by A. 
baumannii. Research from an Australia group reported heteroresistance (resistance of one 
particular strain towards a particular antibiotic) of Colistin in 15 of 16 clinical isolates1, 15 
causing concern that Colistin resistant A. baumannii may be more prevalent than expected.  
 
 
Figure 2.3: Shows the number of citations found in the PubMed database from 1960 to the 
middle of 2011 using either the term ‘colistin’ or ‘colistin resistance’. Source: Biswas et al.31. 
 
This is a concern when addressing the use of Polymyxin E as a therapeutic treatment by itself 
and therefore researchers are looking to the possible use of combination therapies, to 
counteract this resistance. Hornsey et al.13 researching into alternative combination therapies 
found that glycopeptides- Polymyxin E combination therapies are highly active against A. 
baumannii infections in simple invertebrate models of infection. 
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2.2.2 Other antibiotics 
Some studies have suggested that certain hydrophilic antibiotics, such as rifampicin, 
carbapenems, glycopeptides and tetracyclines can work synergistically with colistin but this 
is pathogenic organism dependant 15, 16, 31.  Broad spectrum antibiotics are antibiotic that 
are effective in treating a wide range of infectious microorganisms rather than the restricted 
range of ‘narrow spectrum’ ones. 
 
The selection of antimicrobials chosen for use in combination with colistin was based 
namely on the type of mode of action of the antibiotics within the bacterium ensuring 
diverse mechanisms are present. Based on this chloramphenicol, erythromycin, gentamicin, 
kanamycin, rifampicin and tetracycline were chosen. Gentamicin, Tetracycline, Erythromycin 
and Chloramphenicol were chosen as antimicrobials which disrupt protein synthesis through 
interactions with the ribosomes. Rifampicin was chosen as it disrupts RNA synthesis, 
therefore disrupting protein synthesis through a different mechanism and is bactericidal50, 
Figure 2.4. 
21 
 
 
Figure 2.4: Mode of action for a variety of different bacteriostatic and bactericidal 
antibiotics. Image courtesy of Wiley 2004 Essential Biochemistry. Image accessed July 2014.  
 
2.3  INFECTION HOST MODELS 
To assess the efficiency of antimicrobial treatment in vivo models are routinely used in the 
pharmaceutical industry before clinical trials are undertaken. As human studies are limited to 
individual case reports or retrospective cohort studies, mammalian models are the usual 
source for in vivo research. However many concerns arise when using mammalian models to 
study antimicrobial treatment, these including practical, cost and ethical issues13, 17. As a 
result of this invertebrate models are being developed in our labs and elsewhere as an 
inexpensive and viable alternative to the use of mammalian models.  
Although numerous cases have been reported where several mammalian opportunistic 
pathogens have infected insects only a few studies have investigated whether a significant 
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correlation exists between the virulence in insects and mammals. One explanation for the 
limited research on the use of invertebrates as host models could be that in previous years it 
was naively thought that invertebrates have minimal immune defence systems; an argument 
based around the idea that insects are able to rapidly reproduce offspring and therefore have 
no need to have an intricate immune defence system. However recent research carried out 
by Salzet24 found that similar patterns existed in both vertebrate and invertebrate innate 
immune response when infected by opportunistic pathogens. Jander et al.21 also found that 
a positive correlation exists between virulence of Pseudomonas aeruginosa in mice and 
insects. This supports the idea that invertebrates can be used as an alternative but still 
sophisticated model in antimicrobial investigation. 
 
2.3.1 Galleria mellonella 
Galleria mellonella, the larvae of the greater wax moth (Figure 5) is one of the most described 
invertebrates used as a host model to study pathogens of organisms [50].   Pseudomonas 
aeruginosa, Group A Streptococcus, Listeria monocytogenes, Francisella tularensis, 
Acinetobacter baumannii, Legionella pneumophila, pathogenic fungi and yeasts have been 
investigated13, 15, 20-23, 51-57. Interestingly, a correlation with the virulence of certain microbes 
in mice and G. mellonella has also been established21. G. mellonella is one of the most used 
invertebrates of choice as it has a basic immune response similar to that of mammals. G. 
mellonella immune response system consists of not only structural and passive barriers, but 
also cellular and humoral responses facilitated by the hemolymph system (circulatory system 
in G. mellonella)18, 20. The Galleria model has been used as both a parenteral injection model 
and as an oral infection model58. 
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Figure 2.5: G. mellonella (The Greater Wax moth) 
 
Other invertebrates have been used in the investigation of human opportunistic pathogens, 
such as Drosophila melanogaster19, however these were found to have limitations which 
affected the efficiency of the model such as inability to survive at optimum temperatures of 
37oC. G. mellonella larvae were not found to have these limitations, is cheap and convenient 
for laboratory-based studies22.  
A schematic of the anatomy of G. mellonella is shown below.  Most studies have used the left 
proleg on the underside of the larva for administration of bacteria and drugs (Figure 2.6). 
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Figure 2.6: Anatomy of G. mellonella showing the position of the proleg characterised by 
Smith59. 
 
 
 
Key to Abbreviations 
 
An – Anus, Ant – Antenna, Aplg – Anal Proleg, Ap – Anal Plate, Cp – Cervical 
Plate, FrClp – Frontoclypeus, Hd – Head, Lg – Leg, Ll – Lateral Lobes, Mx – 
Maxillae, Pe – Penaculum, Plg – Proleg, Sap – Suranal Plate, Se – Setae, Sp – 
Spiracle, Tp – Tergal Plate 
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2.3.2  Insect immune response 
The innate immune system, unlike the adaptive immune system of insects and mammals, 
shares a high degree of structural and functional homology. As the innate immune system is 
the mammalians main line of defence in vertebrates, insects have become an attractive 
model which could potentially provide an indication of mammalian response to pathogens17. 
The cellular response of invertebrates is mediated by hemocytes and involves responses such 
as phagocytosis, encapsulation, and clotting60-62. 
 
2.3.3 Wound healing 
Wound healing capabilities of G. mellonella larvae has been extensively studied by Rowley 
and Ratcliffe63. They found immediately after wounding both fat-body and hemolymph of the 
larvae were forced through the wound to form a plug. At the same time, the hemolymph 
coagulated forming vast networks of strand-like material attached to the hemocytes 
underlying the wound. After one to two hours this plug melanized and the cells became highly 
necrotic. Six hours after wounding, there was a massive influx of hemocytes which eventually 
attached to the melanized layer over the wound to form a multicellular sheath. Twelve to 
twenty-four hours later, the epidermal cells underlying the broken cuticle detached and 
migrated across the wound to form a new intact layer. This intricate wound healing process 
is not too dissimilar to that of the mammalian. 
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2.3.4 In vitro analysis of antibiotic susceptibility 
2.3.4.1  Minimum inhibitory concentration 
The MIC of an antibiotic against a pathogen is one of many factors that determine the best 
drug to cure an infection. Although, comparing the MIC of antibiotics against a target 
organism in vitro alone, clinicians may draw the erroneous conclusion that the agent with the 
lowest MIC against a bacterium is the preferred choice.  
 
The following definitions of susceptibility, indifference and resistance have been defined by 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST)64, a joint 
organisation dealing with breakpoints, technical aspects of phenotypic in vitro antimicrobial 
susceptibility testing and functions as the breakpoint committee of the European Medicines 
Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC). 
 
Clinically Susceptible (S): A microorganism is defined as clinically susceptible by a level of 
antimicrobial activity associated with a high likelihood of therapeutic success. 
 
Clinically Indifferent (I):  a micro-organism is defined as intermediate by a level of 
antimicrobial agent activity associated with uncertain therapeutic effect. It implies that an 
infection due to the isolate may be appropriately treated in body sites where the drugs are 
physically concentrated or when a high dosage of drug can be used; it also indicates a buffer 
zone that should prevent small, uncontrolled, technical factors from causing major 
discrepancies in interpretations 
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Clinically Resistant (R): a microorganism is defined as resistant by a level of antimicrobial 
activity associated with a high likelihood of therapeutic failure. 
 
The resulting values obtained via appropriate in vitro susceptibility testing are the clinical 
breakpoints, these are presented as S ≤ x mg/L; I ˃ x , ≤ y mg/L and R ˃ y mg/L 64. 
     
Antibiotic S R 
Ampicillin - - 
Colistin ≤2 mg/L >2 mg/L 
Ciprofloxacin ≤ 1 mg/L > 1 mg/L 
Gentamicin ≤ 4 mg/L > 4 mg/L 
Erythromycin - - 
Tetracycline - - 
Chloramphenicol - - 
Rifampicin - - 
Kanamycin - - 
 
Table 2.1: EUCAST MIC breakpoints for Acinetobacter spp. for the antibiotics to be used in 
this study. N.B. " - " Susceptibility testing not recommended as the species is a poor target 
for therapy with the drug, these drugs should be reported as resistant 64. 
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Ability to predict the resistance of A. baumannii based upon comparisons between MICs and 
predetermined resistance breakpoints may be less certain than other bacteria. A review paper 
by Perez et al. 65 state that due to gaps in the current knowledge of clinical response and 
bacterial mechanisms make existing breakpoints imperfect.   
 
2.3.4.2 Techniques for defining MIC 
Disk susceptibility testing remains the most commonly used technique in clinical microbiology 
laboratories; however the accuracy of colistin use in a disk diffusion assays is unsatisfactory 
because polymyxins diffuse poorly into agar66. EUCAST recommend for MIC testing of colistin 
against Acinetobacter spp. to use an alternative method to determine the breakpoints. Broth 
microdilution has been considered as the optimum method for determining MIC values, 
however this technique can be viewed as impractical and time consuming in clinical 
microbiological laboratories. Etests have been evaluated by both Behera et al. 66 and Galani 
et al.67. Both groups found Etests to have good concordance with broth microdilutions but 
poor accuracy results with disk diffusion, interestingly however, Behera et al. 66 suggested 
that the disk diffusion method could be useful for initial screening in diagnostic laboratories. 
In this study, MIC susceptibility will be evaluated using broth microdilutions. The synergy of 
antibiotics in combination will then be assessed using broth microdilution checkerboard 
assays. 
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2.4 PROJECT AIMS AND OBJECTIVES 
The aim of this project is to establish whether G. mellonella can be used as both a biofilm 
associated infection and planktonic infection model to evaluate the effects of mono- and 
combination therapy against MDR infections. 
 
 
2.2 Objectives  
 
 Establish which/if any of the board spectrum antibiotics used in this study have a 
synergist effect against MDR A. baumannii when used in combination with colistin in 
vitro. 
 To evaluate the effectiveness of the synergistic combinations against MDR A. 
baumannii in the G. mellonella model 
 Investigate a suitable method with will enable us to study the pathogenicity of biofilm 
associated infections G. mellonella 
 
 Establish a biofilm infection model with Galleria mellonella as the host species  
 
 Study different antimicrobial agents in the treatment of biofilm grown A. baumannii 
infection in the G. mellonella model.  
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3 MATERIALS AND METHODS 
3.1 GALLERIA MELLONELLA  
For ease and convenience, G. mellonella were purchased from Live Foods UK. For these 
experiments the larvae estimated to be in the fifth instar of their life cycle, weight of the 
larvae varied slightly, but on average they weighed 250 g ± 25 g. Larvae were rejected if they 
didn’t meet the weight requirements, had any skin decolourisation or obvious abnormalities. 
The larvae were stored in their original container with sawdust at room temperature in the 
microbiology laboratory at the University of Lincoln until required. The larvae were used 
within 4 days of purchase and required no additional food or water.  
 
3.2 BACTERIAL STRAINS 
3.2.1 Acinetobacter baumannii ATCC 19606 
As mentioned before, A. baumannii wild type ATCC strain 19606 was purchased as a cultiloop 
from Oxoid LTD, UK (CL1007). The Cultiloops were stored at 5oC in a fridge in the microbiology 
laboratory at the University of Lincoln until they were required. To culture from the cultiloops, 
working aseptically, one of the disposable inoculation loops containing the preserved 
stabilised microorganism that has been derived from ATCC 19606 was removed from the 
sterile packaging and carefully broken into a sterile glass vial containing 10ml of autoclaved 
LB broth. This inoculum was then incubated statically for 1 hour at 370C, this culture was 
labelled as the original culture. After 1 hour, a sub-culture was made by aseptically 
transferring 1ml of the original culture into 9 ml of sterile LB broth, this was labelled the 
working culture. Both cultures were then incubated at 37oC overnight.  
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3.2.2 A. baumannii Clinical strains 
Other strains of A. baumannii used in this study were gifted from Public Health England, 
Porton Down, UK. The strains included the characterised strain AYE and were received as 
glycerol stocks. 
 
3.2.3 Escherichia coli ATCC 25922 
Like A. baumannii ATCC 19606, E. coli ATCC 25922 was also purchased as a culti loop from 
American Type Culture Collection strains, Oxoid LTD, UK. Both ATCC 19606 and 25922 are 
defined as wild type micro-organisms; that is a strain of a species which has the absence of 
acquired and mutational resistance mechanisms to the drug in question as defined by 
EUCAST.  
 
3.2.4 Culturing medium 
Although several selective and differential media are available for culturing of specific 
Acinetobacter and Escherichia species, both can be cultured readily on routinely used 
laboratory mediums, such as sheep blood agar (BA), tryptic soy agar (TSA) and Luria-Bertoni 
(LB) medium at a 37oC incubation temperature overnight5. In this study LB broth and agar 
was used exclusively for the culturing and maintenance on streak plates and slopes of all 
strains used. To produce LB broth, LB power (1280-1660, Fisher Scientific, UK) 20g was 
suspended in one litre of distilled water, table 3.1.  
For the preparation of agar plates, agar (1.5%w/v) was included in the powder mix. The 
solution was then dissolved by heating with frequent agitation, sterilised in autoclave 121ºC 
for 15 minutes then allowed to cool to 45-50ºC, before mixing and then dispensing into 
plates.   Tryptone and Yeast extract (YE) serve as a source of nitrogen, sulphur and carbon 
32 
 
while YE also contains Vitamin B complex. Sodium chloride provides sodium ions for the 
membrane transport and maintains osmotic equilibrium of the medium. 
 
Formula (g/L) 
Tryptone 10 
Yeast Extract 5 
Sodium Chloride 5 
Agar* 15 
Final pH 7.2 at 25oC 
 
Table 3.1: Formula for the preparation of Luria Bertoni (LB) medium. *Agar should only be 
added for the preparation of agar plates, and excluded when making broth. 
 
For experiments where the need to distinguish between the two different species, A. 
baumannii and E. coli, was required, Membrane Lauryl Sulphate Agar (MLSA) was used. MLSA 
is a selective media type used in for the presumptive detection of coliforms. Coliform groups 
are both aerobic and anaerobic facultative, Gram-negative, non-spore forming rods which 
ferment lactose producing acid at 37oC. On MLSA plates, E. coli appear as yellow colonies as 
they belong to the Coliform group whereas A. baumannii colonies appear as pink colonies. To 
produce MLSA plates, 92.2 grams of the medium were suspended in one litre of distilled 
water, see table 3.2 The solution was then dissolve by heating with frequent agitation, 
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sterilised in autoclave 121ºC for 15 minutes then allowed to cool to 45-50ºC, before mixing 
and then dispensing into plates.   
 
Formula (g/L) 
Casein Peptone 40.00 
Lactose 30.00 
Yeast Extract 6.00 
Sodium Lauryl Sulphate 1.00 
Phenol Red 0.20 
Bacteriological Agar 15.00 
Final pH 7.4 ± 0.2 at 25oC 
 
Table 3.2: Formula for the preparation of Membrane Lauryl Sulphate Agar (MLSA) 
 
3.2.5  Maintenance of cultures 
To maintain a healthy culture of the bacteria throughout this study and also to enable future 
research 2 different stock culturing techniques were employed, cultures streaked on agar 
plates are not considered stock cultures. 
The first one which preserves the culture indefinitely if stored correctly is known as glycerol 
stock. To prepare this culture, 100 ml of 10% glycerol-LB broth was prepared and autoclaved 
sterile. 500 µl of a fresh overnight culture of bacteria was then transferred to a sterile 1.5ml 
Eppendorf to which 500 µl of the glycerol stock. Six Eppendorfs were prepared, 3 were stored 
at -20oC and the other 3 were stored at -80oC. 
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The second culture technique is known as preservation by slopes. To prepare agar slopes, 
agar which has been gently brought to boil to allow for the granules to dissolve, is aliquoted 
out into glass universals then autoclaved. The glass vials are then allowed to cool on a slant 
to produce a sloped agar bed. A single colony is then aseptically taken of an agar plate and 
streaked on to the sloped agar bed in a zigzag pattern. The slopes were then stored on the 
bench top at room temperature. The slope remade every 3 months from fresh cultures. 2 
slopes were made each time, original and working, the original slope were only used if there 
were signs of contamination in the working slope.  
 
3.2.6 Preparation of bacteria for injection 
In order to prepare the bacteria for injection in the G. mellonella model, the bacteria were 
suspended in to an appropriate solution for injection, a saline. This is because the bacteria 
cannot be injected directly from an overnight suspension in LB broth as this could cause the 
larva body system to go into shock and result in death. The chosen saline for this study is 
phosphate buffer saline (PBS), a common buffer saline used in biological research. The 
osmolality and ion concentration of PBS matches that of the human body. PBS was purchased 
from Sigma-Aldrich, UK (P5368). 
 
1ml of an overnight culture (OD ~1.8) was aseptically transferred in to a sterile 1.5ml 
Eppendorf. The culture was then centrifuged at 11, 000 xg for 5 minutes, a sufficient speed 
and duration to spin cells in to a pellet at the bottom of the tube. The supernatant was 
discarded and the pellet was resuspended in 1ml sterile PBS. This process was then repeated 
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so that the pellet was subjected to 2 washes with PBS, then resuspended one last time in 1ml 
of sterile PBS. 
 
3.2.7 Preparation, handling and storage of antibiotics 
Antibiotics were purchased from Sigma-Aldrich® and prepared in stocks, filtered and stored in 
500 µl aliquots in the freezer. 10 ml working stocks of each antibiotics were prepared, see 
table 10. To produce initial stock solutions, erythromycin, tetracycline and chloramphenicol 
were dissolved in 100% ethanol and rifampicin was dissolved in dimethyl sulfoxide. All other 
antibiotics were dissolved in sterile dH2O; Further stock dilutions were made with sterile 
dH2O, see table 3.3. 
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Antibiotic Stock concentration Volume required in ml to 
produce 1024 mg/L 
working stock 
(µl) 
Ampicillin 100 g/L 102.4 
Colistin 10 g/L 1024 
Chloramphenicol 50 g/L 2048 
Ciprofloxacin 10 g/L 1024 
Erythromycin 10 g/L 1024 
Kanamycin 50 g/L 2048 
Rifampicin 50 g/L 2048 
Tetracyline 50 g/L 2048 
 
Table 3.3: Volume required to produce 1ml of 1024 mg/L working stock of the antibiotics 
used in this study. 
 
3.2.8 Statistical analysis 
Kaplan Meier survival/failure statistical analysis estimates the survival function from lifetime 
data and was used in this study to measure the percentage survival of the G. mellonella groups 
over a 96 hour period after given treatment. The significance of the survival the survival 
curves are analysed by Log-rank test which evaluates the equality of the survival distributions 
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between groups (Chi-squared). If the difference between the groups is greater than or equal 
to 0.05 (P=/<0.05), at a confidence limit of 95%, the groups were determined as significantly 
different. SPSS Statisical Analysis software 19 was used. Comparison of the mean percentage 
survival of the larva at the end of the 96 hour test period was made by using one tailed, 
unpaired t test (P =  <0.05) performed using Microsoft Excel 2010. 
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4 ESTABLISHING PATHOGENICITY 
4.1 ESTABLISHING THE MODEL 
4.1.1 Life cycle of G. mellonella 
Before any experiments on the larvae were carried out it was important to know whether the 
larva purchased from Live Foods UK were of the appropriate development stage (instar). As 
mentioned before the larvae selected for use weighed around 250 mg. 16 larvae, which had 
been subjected to no manipulation, were incubated at 37oC for 96 hours. Observations were 
made of the survival of the larvae and also whether there had been any metamorphic 
changes. 
 
4.1.2  Total Viable Counts 
In order to enumerate the quantity of  bacteria injected in to the larva, bacteria from an 
overnight culture was prepared for injection as described above in section 3.1.4 and log 
dilutions were made as described in section 3.2.1 and was repeated until 8 log dilutions had 
been prepared. 100 µl of each dilution was then spread plated on LB agar and incubated at 
37oC for 24 hours. Plates were counted the following day. 
 
4.1.3  Pathogenicity of A. baumannii ATCC 19606 
The pathogenicity of A. baumannii was established by injecting larvae in groups of 16 with 10 
µl of different log dilutions produced from overnight planktonic cultures of ATCC 19606. The 
injections were administered into the top left proleg of each larvae. The 4 log dilutions (100, 
101, 102 and 104) were used to establish the pathogenicity of A. baumannii in G. mellonella, 
bacteria from an overnight culture was prepared for injection as described above in section 
3.1.4. Log dilutions were then made by aseptically transferring 100 µl of the washed bacterial 
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into a sterile Eppendorf which contained 900 µl PBS, the suspension was mixed by gently 
pipetting up and down three times. 100 µl of this dilution was then transferred to a new 
Eppendorf containing 900 µl PBS. This process was repeated to produce 4 log dilutions. 16 
larvae made up each of the test group, a positive control, where larvae were injected with 10 
µl of PBS. A negative control group, a non-injection group, was also included. The larvae were 
incubated at a temperature of 37oC and to ensure the environment had sufficient moisture in 
the air, a bowl of tap water was placed on the bottom shelf. The mortality rate of each larva 
was recorded every 24 hours for 96 hours, larvae were determined as dead if they failed to 
respond to touch. Experimental groups were repeated 3 times, each on separate occasions. 
 
4.1.4 Kill Kinetics of bacterial growth in vivo. 
To determine the kill kinetics of bacterial growth in vivo, larvae were injected with a lethal 
dose of A. baumanni ATCC 19606 (106 CFU/ml), previously described in the method in section 
3.2.2. Every 2 hours individual wax worms were homogenised by grinding using a glass rod in 
1 ml sterile PBS. Eight log dilutions of the homogenised solutions were then prepared and 100 
µl of each dilution was then spread plated on LB agar. Plates were incubated at 37oC for 24 
hours. Plates were counted the following day. LB plates had been supplemented with 100 mg 
ampicillin to ensure only the growth of A. baumannii colonies. Control plates were included; 
Plates with no supplement and spread plates of A. baumannii ATCC 19606 diluted in PBS. 
Gram stains were also performed on random colonies from each plates to check the bacterial 
morphology was that of A. baumannii. 
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4.1.5  Assessing the model against clinical strains of A. baumannii  
To assess the model against clinical strains of A. baumannii bacteria from an overnight culture 
was prepared for injection as described above in section 3.1.4 and log dilutions were made as 
described in section 3.2.1. The model was tested against clinical strains of A. baumannii (AYE, 
W, A13, A14, and A17) to assess the pathogenicity of the clinical strains against the larva. 
Whereas ATCC 19606, a wild type strain, does not possess the resistant mechanisms 
potentially developed by the clinical strains. 
 
4.2 RESULTS AND DISCUSSION 
4.2.1  Life cycle of G. mellonella 
Each stadium is characterized by the slippage of the head capsule of larvae. When larvae 
reach the last stage before pupation, they stop feeding and start building a light silk cocoon68. 
During the incubation time of the larvae which have received no manipulation, no deaths 
were observed. At the end of the 4 days there was evidence that the larva had chewed on the 
filter paper lining the petri dishes and in some cases larva had begun to spin a fine white nest-
like structure, characteristic of the later larval stages. During the final larval stages, the larva 
spins itself a white silken cocoon. After this, the larva enters a quiescent period in which it is 
transformed into a pupa59. None of the larvae showed any signs of reaching this stage within 
the 96 hour observation period.  When larvae were left for a further 3 days, they began to 
show signs of entering the final larval stage, i.e. formed a white silken cocoon. Based on these 
results and the life cycle stages of Greater wax moth68 the larvae were estimated to be in fifth 
instar of the larval stage.  
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A negative control group, one where individuals in the group had received no manipulation, 
was included in each following experiment to ensure larval stage consistency and also to 
monitor the environment. 
 
4.2.2  Total Viable counts 
In order to enumerate viable bacterial colonies, an assumption is made that each bacterial 
colony when immobilised on an agar plate arose from one living (viable) cell, therefore it is 
possible to determine the number of live bacteria defined as colony forming units (CFU) per 
ml of the original culture. The general acceptance range for counting colony forming units on 
agar plates is 30 to 300 colonies. In this study, dilution 10-5 fell within the acceptance range 
of 237 colony forming units grown on the agar plate. 
The CFU/ml of the original culture can be calculated using the following formula:  
CFU/ml = number of colonies per ml plated/Total dilution factor 
A log dilution of 10-5 showed 237 colonies, however only 100 µl of the dilution was plated, 
therefore the number of colonies must be divided by 0.1 ml before being divided by the total 
dilution factor. 
 
Therefore;  
CFU/ml = (237/0.1ml)/10-5 = 2370 x 105 = 2.37 x 108 CFU/ml 
 
42 
 
The above calculation determines the CFU/ml; however the larvae were only injected with 10 
µl of culture, a dilution of 10-2. Therefore it is possible to determine that 10 µl of the original 
culture contained 2.37 x 106 CFU. From this the dilutions injected into the larvae have been 
calculated, see table 3. 
 
Dilution CFU/Larva 
(Amount injected in 10µl) 
100 2.37 x 106 
10-1 2.37 x 105 
10-2 2.37 x 104 
10-3 2.37 x 103 
  
Table 4.1: CFU/Larvae per 10 µl injections, calculated from the original CFU counts. 
 
4.2.3  Establishing pathogenicity of A. baumannii  ATCC 19606 
Previous studies have shown melanisation to be an important marker of the insect innate 
immune system. In a recent study by Wand et al.69 they found melanisation to not only to be 
a marker of an insect’s innate immune system, but they also found a strong correlation 
between the ability for melanin to proliferate within the Galleria as a marker of immune 
evasion and survival. 
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In the present study this was also found to be the case, as the melanisation of the wax larva 
increased across the body and also darken, more likely the larva would not survive the 96 
hour observation period. Melanisation of the larva is a key marker of G. mellonella innate 
immune response, Figure 7. 
 
 
 
 
 
 
 
Figure 4.1: Galleria mellonella infection model a) A healthy caterpillar prior to injection. b) 
Infected larvae. c) Subsequent death of the caterpillar with a high level of melanisation and 
hardening. 
 
After 96 hours, there was a greater survival by larval groups that had been infected with 
planktonic cultures of 103 CFU/larva (93.8%) compared with the groups that had been 
infected with 104 (18.8%), 105 (6.3%) and 106 CFU/Larva (0%), see figure 8. Within 24 hours 
post inoculation, only the group that had received an injection of PBS had 100% survival rate. 
For the group challenged with an injection of 106 CFU/ml, none had survived after 24 hours. 
Overall, A. baumannii was found to be pathogenic towards G. mellonella larvae when 
challenged with levels of 104 CFU or greater. 
a) b) c) 
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Figure 4.2: Kaplan Meier survival curve comparing the pathogenicity of planktonic cultures 
at varying CFU/ml concentrations (103 – 106 CFU/Larva) of Acinetobacter baumannii ATCC 
19606 over a 96 hour test period. 
 
 
The statistical comparison of the pathogenicity groups tested show a high level of significance, 
P<0.05, meaning A. baumannii is increasingly virulent towards G. mellonella wax moth larvae 
in a dose response manner, the higher the CFU injected into the larvae the greater the 
pathogenicity. 
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4.2.4 Kill kinetics of ATCC 19606 
To ensure that the bacteria recovered from the larvae was A. baumannii ATCC 19606 the agar 
plates were supplemented with 100 mg ampicillin. In the absence of an A. baumannii 
infection, there was a baseline level of natural flora recovered from the larvae which was able 
to grow on LB plates, but not on LB plates supplemented with 100 mg ampicillin. A. baumannii 
ATCC 19606 grew well on the ampicillin supplemented plates. 
 
 
 
Figure 4.3: Kinetics of A. baumannii ATCC 19606 bacterial growth within the G. mellonella 
infection model. After initial inoculation, samples were taken at specific time points and 
homogenised in 1 ml PBS and plated on 100mg ampicillin supplemented LB agar plates. 
Average CFU counts have been presented, the error bars represent the standard error 
measurement (±SE). 
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As expected, bacterial numbers increased over time until reaching what seemed to be a 
critical value which caused the death of the wax worm, figure 4.3. 4 hours post inoculation, 
the larva infected with A. baumannii ATCC 19606, had begun to show signs of melanisation 
(Figure 4.4c). The larvae however were still active and behaving in their usual manner. In 
comparison, the control groups injected with PBS showed no signs of melanisation (Figure 10 
b). When plated there was no bacterial growth from the homogenised control groups. The 
CFU at this time point averaged at 1.44 x 104 CFU/larva (+/- 5.9 x 102 SE), see figure 4.4. 
 
 
Figure 4.4: 4 hours post inoculation a) A. baumannii infected control group. B) PBS control. 
C) Kill kinetic group. 
 
6 hours post inoculation the larva infected with A. baumannii ATCC 19606, were beginning to 
move in a sluggish manner and began to show signs of melanisation (Figure 4.5c). The control 
groups injected with PBS still showed no signs of melanisation (Figure 4.5b). When plated 
there was no bacterial growth from the homogenised control groups. The CFU at this time 
point averaged at 1.70 x 106 CFU/larva (+/- 9.94 x 104 SE), a 100 fold greater than the CFU 
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value 2 hours before. SE bars show confidence in the repeated groups that there is little 
variance in the colony counts recovered, see figure 4.3. 
 
Figure 4.5: 6 hours post inoculation a) A. baumannii infected control group. B) PBS control. 
C) Kill kinetic group. 
 
8 hours post inoculation there is little change in the behaviour and the degree of melanisation 
of the larvae. The control groups injected with PBS still showed no signs of melanisation 
(Figure 4.6b). When plated there was no bacterial growth from the homogenised control 
groups. The CFU at this time point averaged at 6.14 x 106 CFU/larva (+/- 7.73 x 105 SE), 
approximately triple the CFU value 2 hours before. SE bars show confidence in the repeated 
groups that there is little variance in the colony counts recovered, see figure 4.3. 
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Figure 4.6: 8 hours post inoculation a) A. baumannii infected control group. B) PBS control. 
C) Kill kinetic group. 
 
10 hours post inoculation, 2 of the larvae failed to respond to touch after 1 minute of gentle 
agitation. The control groups injected with PBS still showed no signs of melanisation (Figure 
4.7b) and when plated there was no bacterial growth from the homogenised control groups. 
The CFU at this time point averaged at 2.39 x 109 CFU/larva (+/- 4.67 x 108 SE), approximately 
a 1000 fold greater than the CFU value 2 hours before. SE bars show confidence in the 
repeated groups that there is little variance in the colony counts recovered, see figure 4.3. 
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Figure 4.7: 8 hours post inoculation a) A. baumannii infected control group. B) PBS 
control. C) Kill kinetic group. 
 
By 12 hours post infection none of the larvae were responding to touch and therefore were 
declared dead. The control groups injected with PBS still showed no signs of melanisation and 
when plated there was no bacterial growth from the homogenised control groups. The CFU 
at this time point averaged at 1.16 x 1010 CFU/larva (+/- 4.44 x 109 SE), approximately a 10 
fold greater than the CFU value 2 hours before (Figure 4.3). Between 10 and 12 hours post 
inoculation death of the larvae occurs, which means it is possible to determine that the critical 
value at which death of the larvae occurs around 109 CFU/Larva.   
24 hours post inoculation, all of the larvae had been dead for at least 12 hours. Just by looking 
at the graph there is an obvious decline in viable cell numbers (Figure 4.3). The error bars 
above and below the mean value show there to be a much wider distribution of the original 
data values which tells us at this point, the samples taken were much more varied. One 
explanation for this could be due to the variability in nutritional resources available to sustain 
the bacteria. Another explanation for the decline in numbers could be the changing 
environment upon the death of the larva, i.e. potentially competing bacteria that begin to 
50 
 
colonise the body of the dead larva. However the process and rate at which the larvae begin 
to decompose, as far as the author is aware, is unknown. What is important here is to 
understand that the bacteria were still able to survive within the wax worms for at least 
another 12 hours after the larva were noted as dead. 
 
4.2.5  Assessing the model with clinical strains of A. baumannii  
Assessing clinical strains in the model is interesting to investigate how different strains 
respond in the model. Such strains may possess different virulent genes which would impact 
the strains pathogenicity towards the larva, and the effect the possible treatment envisaged 
in the clinic. 
In the present study a range of the following clinical strains gifted from Public Health England 
were assessed in the G. mellonella model. 
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Clinical Strain: AYE 
 
Figure 4.8: Kaplan Meier survival curve comparing the pathogenicity of planktonic cultures 
at varying CFU/ml concentrations (103 – 106 CFU/Larva) of A. baumannii clinical strain AYE 
over a 96 hour test period. 
 
 
After 96 hours, there was a greater survival by larval groups that had been infected with 
planktonic cultures of 103 CFU/larva (50.0%) compared with the groups that had been 
infected with 104 (6.3%), 105 (0%) and 106 CFU/Larva (0%), see figure 14. Within 24 hours post 
inoculation, only the group that had received an injection of PBS had 100% survival rate. For 
the group challenged injections of either 105 or 106 CFU/ml had 0% survival after 24 hours. 
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Overall, Strain AYE was found to be pathogenic towards G. mellonella larvae when challenged 
with levels of only 104 CFU or greater. 
 
Clinical Strain: W 
Figure 4.9: Kaplan Meier survival curve comparing the pathogenicity of planktonic cultures 
at varying CFU/ml concentrations (103 – 106 CFU/Larva) of A. baumannii clinical strain W 
over a 96 hour test period. 
 
 
Strain W was highly pathogenic towards the larval groups. Groups infected with planktonic 
cultures of 103 and 104 CFU/larva had a survival rate of 6.3% after 96 hours post inoculation. 
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Groups injected with 105 and 106 had 0% survival after 24 hours. Overall, Strain W was found 
to be pathogenic towards G. mellonella larvae when challenged with levels of 103 CFU or 
greater. 
 
Clinical Strain: A2 
 
Figure 4.10: Kaplan Meier survival curve comparing the pathogenicity of planktonic cultures 
at varying CFU/ml concentrations (103 – 106 CFU/Larva) of A. baumannii clinical strain A2 
over a 96 hour test period. 
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After 96 hours, there was a greater survival by larval groups that had been challenged with 
doses of 103 and 104 CFU/larva (56.3%) compared with the groups that had been infected 
with 105 (25.0%) and 106 CFU/Larva (12.5%), see figure 16. Groups that had received an 
injection of PBS had 100% survival rate. Overall, Strain A2 was found to be the least 
pathogenic strain to have infected G. mellonella larvae, however the statistical comparison of 
the pathogenicity groups tested show a high level of significance, P = 0.01, meaning strain A2 
is increasingly virulent towards G. mellonella wax moth larvae in a dose response manor, the 
higher the CFU injected into the larvae the greater the pathogenicity is. 
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Clinical Strain: A13 
 
Figure 4.11: Kaplan Meier survival curve comparing the pathogenicity of planktonic cultures 
at varying CFU/ml concentrations (103 – 106 CFU/Larva) of Acinetobacter baumannii clinical 
strain A13 over a 96 hour test period. 
 
 
 
After 96 hours, there was a greater survival by larval groups that had been challenged with 
doses of 103 CFU/larva (37.5%) compared with the groups that had been infected with 104 
(12.5%), 105 (0%) and 106 CFU/Larva (0%), see figure 17. Within 24 hours post inoculation, 
only the group that had received an injection of PBS had 100% survival rate. For the group 
challenged injections of 106 CFU/ml had 0% survival after 24 hours. Overall, Strain A13 was 
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found to be pathogenic towards G. mellonella larvae when challenged with levels of 103 CFU 
or greater. 
 
Clinical Strain: A14 
 
 
 
Figure 4.12: Kaplan Meier survival curve comparing the pathogenicity of planktonic 
cultures at varying CFU/ml concentrations (103 – 106 CFU/Larva) of Acinetobacter 
baumannii clinical strain A14 over a 96 hour test period. 
 
 
Strain A14 was found to be highly pathogenic towards G. mellonella. After 96 hours, there 
was a greater survival by larval groups that had been challenged with doses of 103 CFU/larva 
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(25.0%) compared with the groups that had been infected with 104 (12.5%), 105 (0%) and 106 
CFU/Larva (0%), see figure 18. Within 24 hours post inoculation, only the group that had 
received an injection of PBS had 100% survival rate. For the group challenged injections of 106 
CFU/ml had 0% survival after 24 hours. Overall, Strain A14 was found to be pathogenic 
towards G. mellonella larvae when challenged with levels of 103 CFU or greater. 
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Clinical Strain: A17 
 
 
Figure 4.13: Kaplan Meier survival curve comparing the pathogenicity of planktonic cultures 
at varying CFU/ml concentrations (103 – 106 CFU/Larva) of Acinetobacter baumannii clinical 
strain A17 over a 96 hour test period. 
 
 
After 96 hours, there was a greater survival by larval groups that had been challenged with 
doses of 103 CFU/larva (62.5%) compared with the groups that had been infected with 104 
(31.3%), 105 (18.8%) and 106 CFU/Larva (0%), see figure 19. Within 24 hours post inoculation, 
only the group that had received an injection of PBS had 100% survival rate. For the group 
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challenged injections of 106 CFU/ml had 0% survival after 24 hours. Overall, Strain A17 was 
found to be pathogenic towards G. mellonella larvae when challenged with levels of 104 CFU 
or greater. 
 
Overall, The statistical comparison of the pathogenicity groups tested show a high level of 
significance, P < 0.05, meaning A. baumannii is increasingly virulent towards G. mellonella wax 
moth larvae in a dose response manner, the higher the CFU injected into the larvae the 
greater the pathogenicity.  
 
4.3 SUMMARY OF RESULTS  
As expected from the kill kinetics experiment focusing on A. baumannii ATCC 19606, the 
bacterial numbers increase over time until reaching a critical value between 1011 and 1012 CFU 
at which point causes death of the larvae, this happened within 12 hours after initial 
inoculation. 
Planktonic cultures of all strains were found to be increasingly virulent towards G. mellonella 
in a dose response manner. That is the more CFU injected into the larvae, the increased 
likelihood of death. A. baumannii ATCC 19606 was found to be pathogenic towards G. 
mellonella at 104 CFU/ml. The clinical strains were similarly pathogenic towards G. mellonella. 
These results support the idea that the wax moth larva model could be a useful tool in 
studying the pathogenicity of problematic pathogenic bacteria. 
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5 IN VITRO SUSCEPTIBILITY AND ANTIMICROBIAL SYNERGY AGAINST 
PLANKTONIC A. BAUMANNII 
5.1 INTRODUCTION 
MIC assays show the minimum concentration of antibiotic required to result in no growth of 
bacteria. The MIC is important in detecting possible drug resistance in pathogenic bacteria 
and to assure susceptibility to the drugs of choice for particular infections70.  
The MIC in this study was defined as the lowest concentration of antibiotic that completely 
inhibited the growth of colonies detected by the naked eye. MIC values needed to be 
determined before the checkerboard MIC assay could be performed. Concentrations of 
antibiotics for the checkerboard assay need to range from four to eight times the expected 
MIC, to at least 1/8 to 1/16 the expected MIC in the final panel in order to observe the 
occurrence and magnitude of synergy or antagonism. 
Comparisons were made to EUCAST64 for their defined breakpoints. Breakpoints are the limits 
which define susceptibility and resistance, section 2.3.4.1. 
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5.2  MATERIALS AND METHODOLOGY 
5.2.1 Preparation of inoculum 
Bacteria were grown in the overnight culture then diluted to an O.D. reading of 0.01 [69]. 
Cultures were diluted by taking O.D. readings, and then used the following equation to 
calculate the required volume of the overnight culture which was needed to be added to 
fresh sterile broth: 
 
OD1V1 = OD2V2 
Where: 
OD1 = Initial OD reading of the overnight culture 
V1 =? The unknown volume 
OD2 = Desired OD reading, which in this case is 0.01. 
V2 = 10 ml 
 
Once V1 has been calculated, this volume of the overnight culture can be added to the fresh 
broth, check reading equals an O.D. of 0.01. The adjusted inoculum is equal to 
approximately 107 CFU/ml (based on O.D. v CFU/ml calibration curve not shown).  
 
5.2.2 MIC microbroth assay 
To determine the MIC for each of the antibiotics used against A. baumannii 96 well microtitre 
plates were prepared in advance by following a standard laboratory MIC microdilution assay 
protocol71. Final concentrations of antibiotics ranged from 0.5 - 512 mg/L for erythromycin, 
rifampicin, ampicillin, chloramphenicol and ciprofloxacin MICs and 256 – 0.25 mg/L for 
colistin. Plates containing antibiotics were stored at -20oC for maximum of a week before use 
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and thoroughly defrosted before use; each plate contained 3 replicates and negative 
antibiotic controls. 100 µl of the adjusted inoculum (described in section 4.1.1) was added to 
the pre-prepared antibiotics and sealed using parafilm. Plates were incubated statically at 
37oC for 24 hours.  
 
5.2.3 Minimum Bactericidal Concentration (MBC) 
The MBC is the concentration at which an antibiotic is able to complete eradicate the bacteria. 
To do this, 10 µl spots of 3 wells either side of the first well to show no turbidity were plated 
on Müller Hinton agar plates and incubated for 24 hours at 37oC; the lowest concentration 
where there was no growth was determined as the MBC. 
 
5.2.4 Checkerboard MIC Assays 
Antibiotic synergy was determined in vitro using the well-established microdilution broth 
checkerboard assay technique70, 72. The broad spectrum antibiotics (working concentrations 
ranging from 0.125 mg/L – 64 mg/L or 0.5 mg/L to 256 mg/L depending on initial MIC) were 
serially diluted across the ordinate whilst colistin (working concentrations 0.06 mg/L – 4 mg/L) 
was diluted along the abscissa. 100 µl of the adjusted inoculum was added and each plate 
was sealed and incubated statically at 37oC for 24 hours.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 MIC 
EUCAST64 publish data on clinical MIC breakpoints (Table 4.2) provide investigators and 
clinicians information on the susceptibility of bacterial strains to different antimicrobials, see 
section 2.3.4.1. 
 
Antibiotic MIC breakpoint 
(mg/L) 
Disk content 
(µg) 
Zone diameter 
breakpoint (mm) 
Notes 
S ≤ R > S ≤ R < 
Ampicillin - -  - - Susceptibility testing of 
Acinetobacter spp. to penicillins 
is unreliable. In most instances 
Acinetobacter spp. are resistant 
to penicillins. 
Ciprofloxacin 1 1 5 21 21  
Erythromycin - -  - -  
Tetracycline - -  - -  
Chloramphenicol - -  - -  
Colistin 2 2  See 
note 
See 
note 
Use an MIC method 
Rifampicin - -  - -  
 
Table 5.1: EUCAST Clinical Break points for Acinetobacter spp. ‘-’ means no breakpoint 
information, susceptibility testing is not recommended. Table has been reproduced from 
EUCAST64. 
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Table 5.2: MIC values of a range of antibiotics tested against A. baumannii 19606. 
 
Comparing the values from the microbroth assay performed in this study to the clinical 
breakpoints as determined by EUCAST, it was determined that A. baumannii ATCC 19606 was 
susceptible to colistin only. The strain was determined as resistant to ciprofloxacin. For all the 
other antimicrobial agents tested in this study it is impossible to determine whether A. 
baumannii is susceptible or resistant as there are no break point values for these agents; 
however the values for all antibiotics, excluding rifampicin and tetracycline, were very high. 
Although EUCAST recommend agents without break points should not be tested, in this study 
the MIC values for these agents needed to be determined in order to perform a checkerboard 
MIC assay. The synergist activity of ampicillin will not be tested due to the high MIC value 
recorded here. 
Antibiotic MIC 
µg/ml 
MBC 
µg/ml 
Ciprofloxacin > 16 16 
Erythromycin > 32 64 
Chloramphenicol > 32 32 
Kanamycin > 8 16 
Tetracycline > 1 1 
Colistin > 0.25 1 
Rifampicin > 2 2 
Ampicillin >512 512 
Gentamicin > 32 32 
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5.3.2  Comparison to International antimicrobial wild type MIC distributions of 
microorganisms 
International MIC distributions are graphical representations of different MIC ranges collated 
together from all kinds of different sources across the world. The MIC values have been 
obtained through a variety of different methodologies and although these different 
methodologies do not always yield the exact same MIC result, values rarely vary by more than 
one doubling dilution step70.  By combining these MIC values into one graph, the distribution 
graphs are able to address the variation between different investigators and methodologies. 
The benefits of this mean that the information can be used as reference material for 
determining clinical breakpoints, epidemiological cut-off values, MIC ranges of wild type 
organisms. In addition, the MIC distributions also serve as an internal reference for calibration 
of antimicrobial susceptibility testing methods70. 
MIC distributions have many benefits, however they have also been heavily criticised due to 
their limitations. Data used in these has been collated from a wide variety of sources, time 
periods and some include high proportions of resistant organisms therefore may not be 
entirely applicable. Also many different studies use varying MIC ranges making a comparison 
using these results difficult, especially when comparing the upper part of the MIC ranges as 
they may not exist. 
 
In terms of the current study the international MIC distributions were used as an internal 
standard. For antimicrobials colistin, ciprofloxacin, rifampicin and gentamicin distribution 
data was available, Figure 5.1. The MIC values fall within the MIC distribution values reported 
by EUCAST.   Data was not available on the EUCAST for the MIC distributions of erythromycin, 
chloramphenicol, kanamycin and ampicillin against A. baumannii wild-types organisms. 
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Figure 5.1 MIC distributions for a) colistin b) ciprofloxacin c) gentamicin d) rifampicin against 
pathogenic A. baumannii collected from multiple sources, geographical areas and time 
periods (Solid lines = wild type). EUCAST 201464. 
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5.3.3  Checkerboard Minimum Inhibitory Concentration Assay 
Degree of synergy between antimicrobial drugs was expressed in terms of the Fractional 
Inhibitory Concentration (FIC), which can be calculated using the following equation: 
 
FIC = MIC of drug in combination/MIC of drug alone 
 
From the calculated FIC values the fractional inhibitory concentration index (FICI) was defined 
as the lowest FIC value. Antibiotic concentrations were defined as synergistic if the FICI ≤ 0.5, 
indifferent if the FICI between 0.5 and 4 or antagonistic if the FICI >4.072. If combinations are 
determined as synergistic, then the effect of the two antibiotics used together is greater than 
if the agents were to be used alone. 
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Antibiotic FICI Synergistic/Indifferent/Antagonist 
Ciprofloxacin 0.63 Indifferent 
Erythromycin 0.37 Synergistic 
Kanamycin 0.75 Indifferent 
Tetracycline 0.75 Indifferent 
GentamIcin 0.75 Indifferent 
Chloramphenicol 0.63 Indifferent 
Rifampicin 0.13 Synergistic 
 
Table 5.3: Determination of synergy/indifference/antagonism for various broad spectrum 
antibiotics in combination with colistin. 
 
Erythromycin alone displayed little activity against of A. baumannii 19606 MIC >32 mg/L, table 
5.2, and due to the insufficient information on the clinical breakpoints for erythromycin 
against A. baumannii it was impossible to determine whether A. baumannii was resistant or 
susceptible to erythromycin, table 5.1. It is for this reason, EUCAST64 recommended that 
erythromycin should not be used as a treatment option for such infections as the therapeutic 
outcome is unknown and likely poor. However the combination of erythromycin and colistin 
resulted in an FICI of 0.37 mg/L, which means the combination is synergist, table 5.3. 
Therefore it is possible to conclude from this that when used in combination with each other 
the two antibiotics produce an effect that is greater than if they were to be used alone. What 
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this means in the present study is that when the combination of the antibiotics is 
administered to individuals in models deliberately infected with A. baumannii it is expected 
that a greater number of individuals will survive the infection. 
 
For rifampicin, again the insufficient information available on the clinical breakpoints for 
rifampicin against A. baumannii it was impossible to determine whether A. baumannii was 
resistant or susceptible to rifampicin. EUCAST in their clinical breakpoint table recommend 
that rifampicin should not be used in susceptibility testing against A. baumannii infections, 
however the MIC value from this study suggest a high level of activity, which suggests activity 
against A. baumannii ATCC 19606. When used in combination with colistin, the FICI was 
determined as 0.13 (table 4.8) the lowest calculated FICI of all the antibiotic combinations 
tested. As the FICI is below 0.5, the combination is defined as synergistic, producing an effect 
combined that is greater than if either antibiotic was to be used alone. 
 
Due to the insufficient information on the clinical breakpoints for kanamycin against A. 
baumannii it was impossible to determine whether A. baumannii was resistant or susceptible 
to kanamycin, table 5.1. It is for this reason, EUCAST64 recommended that erythromycin 
should not be used as a treatment option for such infections as the therapeutic outcome is 
unknown and likely poor. In combination with colistin the FICI was determined as 0.75 (table 
5.3), an FICI value greater than 0.5 but lower than 4 therefore the combination has been 
defined as indifferent, therefore therapeutic success is no greater than if the agents were to 
be used alone. Tetracycline, chloramphenicol, ciprofloxacin and gentamicin also all had FICI 
values calculated which fell within the indifferent range and therefore the combination with 
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can be determined as indifferent, indicating there would not be any advantage to combining 
the two antibiotics for the treatment of MDR A. baumannii72. 
 
 
5.3.4  Limitations 
Due to the insufficient information on the clinical breakpoints for many broad spectrum 
antibiotics against A. baumannii this makes it incredibly hard for investigators and clinicians 
to research/make decisions when I comes to approaching the MDR problems surrounding A. 
baumannii. To add to the lack of information available is an interesting point that even when 
the major organisations that define the breakpoints (CLSI and EUCAST), these have been 
shown to be different for many of the key antibiotics used in the therapy of A. baumannii 
infections5. This conflicting information and the fact that EUCAST report insufficient evidence 
for the majority of antibiotics leads to much confusion surrounding the treatment options 
available for infections caused by MDR A. baumannii64. The impact this has on research is a 
lack of understanding of appropriate dosing levels and agents. In a recent conference meeting 
hosted by ESCMID on reviving old antibiotics, it was concluded that the limiting knowledge of 
the behaviour of old antibiotics and the resistant mechanisms of MDR bacteria has led to the 
misuse and mistreatment of MDR infections73. MICs of antibiotics against such bacteria need 
to be reviewed to gain a better insight into possible successful therapeutic options. 
 
Colistin is a cationic antibiotic which creates many problems throughout the preparation and 
testing of this antibiotic, due its affinity to bind to negatively charged plasticware. The binding 
of colistin to the walls of plastic Eppendorfs and 96 well plates means there is less ‘free’ 
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colistin available to act upon the bacteria. This could impact the concentrations originally 
prepared and also the activity of colistin in vitro. Unfortunately it is also the cationic 
characteristic of colistin which prevents antibiotic disk susceptibility being carried out. The 
cationic charge of the colistin from diffusing through Müller Hinton agar; these issues have 
called for EUCAST to formulate a method in which the MIC testing of colistin is standardised. 
In a recent conference meeting hosted by ESCMID73, issues surrounding the conflicting results 
being published involving colistin antibiotic testing was raised and it was concluded more 
work needed to be done to standardise the testing and for the evaluation of antimicrobials 
against MDR bacteria. 
The checkerboard MIC assay is widely used for the evaluation of in vitro synergy for multiple 
agents, however problems with the performance, standardisation and interpretation have 
been discussed74. One major limitation discussed is the inherent error of the two-fold dilution 
of the antibiotics being assessed. The difference between each concentration is half of its 
predecessor, which leads to the precision of this technique being questionable. However 
although these limitations are concerning, it is important to bear in mind that the principle of 
examining the growth of bacteria at multiple dilutions of combined antibiotics in vitro, is valid 
for the assessment of synergy but may be further developments need to be undertaken to 
improve this74. 
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5.4  SUMMARY OF RESULTS 
Of all the antibiotics, only rifampicin and erythromycin where calculated to be synergistic 
when in combination with colistin. All other antibiotic combinations with colistin were found 
to be indifferent, meaning the activity of the antibiotic in combination with colistin did not 
inhibit or improve the activity of the drug against A. baumannii. None of the combinations 
were found to be antagonists. However although this suggests that the combinations will 
have little improvement when evaluated in vivo, previously combinations assessed in vivo 
that in vitro had shown to be indifferent, significantly improved the survival rates13.  
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6 IN VIVO EVALUATION OF ANTIMICROBIAL COMBINATIONS 
6.1 INTRODUCTION 
Based on the MIC/FICI values from the previous section, it was possible to determine that 
erythromycin and rifampicin are most likely to have a synergist effect when combined with 
colistin in treating A. baumannii infections. To evaluate this in vivo, the G. mellonella model 
was employed. 
 
6.2  METHODS AND MATERIALS 
6.2.1 Mono-therapy  
To investigate the efficacy of colistin, erythromycin and rifampicin against A. baumannii 
infections, groups of 16 larvae were challenged with lethal doses of A. baumannii then treated 
with a single dose of antibiotic, see table 5.1 for dosage. Doses used in this experiment were 
based on human doses previously described in the literature, see table 6.1. Control 
pathogenicity and PBS groups were included in each repeat, experiments were repeated 
three times. Immediately after each treatment, the larvae were incubated at 37oC and their 
survival rate recorded every 24 hours over 96 hour period.   
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Antibiotic Dose 
Colistin 2.5 mg/kg15 
Erythromycin 50 mg/kg75 
Rifampicin 8 mg/kg76 
Gentamicin 10 mg/kg13 
Chloramphenicol 12.5 mg/kg77 
Ciprofloxacin 20 mg/kg18 
Ampicillin 20 mg/kg22 
Kanamycin 7.5 mg/kg78 
 
Table 6. 1: Dose calculated based on current literature for hospital acquired infections. 
 
6.2.2 Combination therapy 
To investigate the efficacy of the antibiotic combinations, larvae groups were injected at the 
doses described above and injected with antibiotics in combination. To allow for the trauma 
associated with double injections, uninfected larvae inoculated twice with 10 μl of PBS were 
also used. Immediately after each treatment, the larvae were incubated at 37oC and their 
survival rate recorded every 24 hours over 96 hour period.    
Control pathogenicity and PBS injected larvae were included in each repeat for all G. 
mellonella experiments. Groups where 2 or more larvae from the control groups died were 
rejected. 
   
6.3 RESULTS AND DISCUSSION 
 As suggested in the in vitro analysis of ciprofloxacin, gentamicin, ampicillin, kanamycin and 
chloramphenicol in combination with colistin, these combinations were unsuccessful in 
improving the survival rate of G. mellonella groups that had been experimentally infected 
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with pathogenic levels of A. baumannii. All groups treated with these antibiotic combinations 
gave a very poor survival rate ≤6.25% and due to this, results have not been shown. 
However, the combination of both erythromycin and rifampicin with colistin was significantly 
more active than either drug alone in the infected G. mellonella model, table 6.2.  Rifampicin 
combinations resulted in the highest percentage survival and therefore most active 
combination against A. baumannii infected groups. 
 
 
Table 6.2: antimicrobial treatment efficacy against planktonic A. baumannii ATCC 19606 
infections evaluated in a G. mellonella infection model 
 
Larval groups infected with lethal planktonic cultures of A baumannii ATCC 19606, following 
treatment with colistin alone, the survival rate was only 14.58% (±3.61 sdp). Treatment with 
colistin in combination with rifampicin (43.75%  ± 3.61 sdp) or erythromycin (35.42% ± 7.22 
sdp) showed combination therapy was significantly more active in treating ATCC 19606 lethal 
infections (t test, P = < 0.01 for both). 
 
 
Antibiotic % G. mellonella survival after 96 hours 
Treatment alone Treatment in combination 
with colistin 
Erythromycin 4.17±3.61 35.42±7.22 
Rifampicin 12.5±6.25 43.75±3.61 
Colistin 14.58±3.61 - 
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Figure 6.1: Kaplan Meier survival curve comparing the treatment of lethal A. baumannii 
ATCC 19606 infections with rifampicin and colistin alone and in combination in the G. 
mellonella infection model. Survival was monitored every 24 hours over 96 hour period. 
Graph represents results from a single typical test. 
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Figure 6.2: Kaplan Meier survival curve comparing the treatment of lethal A. baumannii 
ATCC 19606 infections with erythromycin and colistin alone and in combination in the G. 
mellonella infection model. Survival was monitored every 24 hours over 96 hour period. 
Graph represents results from a single typical test. 
 
 
 
Both graphs show typical infection groups that have been treated with either erythromycin 
or rifampicin in combination with colistin. Both treatment combinations were found to 
significantly improve the survival rate of the infected larval groups P<0.05. 
It has been proposed that the synergistic effects observed with colistin/ polymyxin B are due 
to the disruption of the outer membrane permeability. Although this interpretation is 
reasonable, the dual action of polymyxin antibiotics introduces a degree of uncertainty.  
Once the outer membrane has been disrupted by colistin (a non-lethal action), free colistin 
are able penetrate the inner layers of the cell envelope resulting in leakage of the cytoplasmic 
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contents, which is lethal13, 15, 31. Both actions can occur at the same polymyxin concentration, 
however studies have found that it is possible to separate the two actions with the outer 
membrane permeabilisation activity occurring at a lower dosage.   
Previous studies report that colistin when tested in vitro initially displays bactericidal activity 
against clinical strains of A.baumannii but this appears to be overcome after 24 hours15. The 
present study agrees that colistin does not possess sufficient bactericidal activity to overcome 
initial A. baumannii infections in the first phase of treatment. Since colistin demonstrates 
excellent synergy in vitro with both erythromycin and rifampicin, and larval survival is 
significantly increased in the combination model of infection, suggesting there is sufficient 
bactericidal activity within the combinations that is able to overcome the infection.  Cai et 
al.16 analysed antimicrobial strategies to avoid colistin resistance of A. baumannii comparing 
a number of patient studies evaluating combination therapies of colistin with a range of 
antibiotics, including rifampicin. Rifampicin/colistin combinations were shown in vitro, in vivo 
and in clinical reports to be promising therapeutic options against MDR A. baumannii 
infections. The model evaluated in the present study supports these finding and also provides 
evidence on the use of the rifampicin/colistin combination therapy against A. baumannii 
infections in a simple, cheap and ethically acceptable model. 
Other macrolide antibiotics in combination with colistin have been shown previously to be 
synergists in vitro; Timurkaynak et al. 79 found azithromycin in combination with colistin to be 
synergistic against three different A. baumannii isolates. In the present study, the macrolide 
erythromycin was found to both be synergist in vitro and significantly improved survival of 
the G. mellonella. 
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6.4 SUMMARY OF RESULTS  
When assessed in vivo not all of the colistin combinations were found to be effective and 
significantly improve the survival of the larva. It was only the combination of erythromycin 
and rifampicin with colistin which was calculated to be significantly more active than not only 
the drugs alone but also the other combinations in the infected G. mellonella model.  
Rifampicin combinations resulted in the highest percentage survival overall and therefore 
most active combination against the infected groups. 
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7 BIOFILM FORMATION, PATHOGENICITY AND TREATMENT 
7.1 INTRODUCTION 
Bacteria have evolved to become proficient at adapting to not only their extracellular 
surroundings but also environmental conditions, which has made it possible for them to 
attach and form biofilms in nearly all habitats where life can exist. This has resulted in major 
health concerns and economic burden in both hospital and industrial environments37, 80-87. 
According to reports by a team of researchers at the Centre for biofilm Research in Montana, 
it was not until the 1970s that scientists began to appreciate that bacteria predominately 
exists as biofilms. Before this, bacteria was perceived as a unicellular life form existing in a 
pure-culture paradigm for the results to be experimentally valid, when in fact biofilm 
associated microbes are very different from their planktonic counterpart on a surface, 
displaying an altered phenotype in terms of growth rates and gene transcription, when 
compared to planktonic cells of the same organism36, 88. This has resulted in an inherent error 
in that this is not a true representation of how the majority of bacteria exist outside the 
laboratory environment42. As previously discussed in section 2, biofilms do not exist as pure 
culture single species, rather a multispecies communities encased within the biofilm matrix.  
In the present study the biofilm-associated suture model was preliminarily used to develop a 
novel method with which biofilm associated infections could be studied and also to assess 
whether a mixed species biofilm would have an effect on the resistance of A. baumannii.  The 
organisms which will be studied alongside nosocomial important strain A. baumannii ATCC 
19606 is E. coli ATCC 25922. 
81 
 
E. coli ATCC 25922 is an ideal strain to be used in laboratory investigations as it has been 
reported as a suitable surrogate for the human pathogenic strain E. coli O157:H7, a common 
cause of food poisoning, due to the similar biofilm forming capabilities37, 89, 90. 
 
7.2 MATERIALS AND METHODS 
7.2.1 Biofilm model 
To study the biofilm infection within the G. mellonella model a suitable material needed to 
be selected to which the bacteria could adhere to and also easily injected in to the model. 
Mammalian infection models use to investigate biofilm infections associated with indwelling 
devices use actual devices to simulate the infections in vivo [86]. Due to the size of the G. 
mellonella larvae, it is not a viable option to use such simulations. Therefore an alternative 
material was required. Based on the traditional staphylococcal string infection model in 
rodents, where ‘string’ contaminated with bacteria was sewn under the skin of mammalian, 
a method was formulated in which bacteria would be grown on to the ‘string’ and 
manipulated into the G. mellonella model. 
 
Varying lengths of the suture was initially cut to determine a manageable length of suture 
which would enable it to insert into the larva; lengths ranged from 1 to 3 mm. Ultimately it 
was decided that the suture would be cut into 3mm pieces as this allowed for easy handling 
and accurate cutting. 
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Figure 6.1: scaled photo of cut surgical suture measuring 3 mm. 
7.2.2 Insertion trauma  
Previous preliminary work carried out by the established whether there was any difference 
between injecting using a pipette and sharpened pipette tips (Eppendorf, US) verses using a 
Hamilton 10 µl syringe needle (Sigma-Aldrich, UK). To develop a method for inserting the 
suture pieces in to the G. mellonella, individual sterile pieces of suture were aseptically 
inserted in to the bottom of sterile p200 pipette tips (Sarsteadt, Germany) which had been 
sharpened to an angle that mimicked the needle of the SGE 10µl syringe needle. 
In order to insert the suture in to individual larvae, the sharpened pipette tip penetrated the 
left proleg, then with the aim of a sterile stainless steel wire the suture piece was very gently 
inserted in to the body of the larvae. A sample size of 16 larvae was used in each test situation, 
and control included groups which received no manipulation and groups which mimicked the 
trauma of the suture being inserted. All groups were incubated at 37oC and the survival rates 
were monitored for 96 hours and the results statistically analysed using Kaplan Meier survival 
analysis.  
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7.2.3 Establishing growth on suture surface 
Once it had been establish that the larvae could survive the trauma of being injected with 
sterile suture via a pipette tip, the growth of each species both individually and as a mixed 
culture needed to be established upon the individual suture pieces. To do this for the single 
species attachment, an overnight culture of each species was first adjusted to a culture with 
an O.D. of 0.01, see section 5.2.1.  2 ml of the adjusted inoculum was added to 5ml bijous 
containing approximately 20 autoclaved suture pieces and incubated at 37oC with RPM of 125 
for 24 hours. Individual suture pieces were then removed aseptically and washed thoroughly 
with PBS.  For the mixed species attachment, the individual inoculums were adjusted to 
cultures with O.D. values of 0.01, and at a ratio of 0.42:0.29 as previously defined (P.Skipper 
personal communication at the University of Lincoln) 100 ml of mixed species inoculum was 
produced 2 ml of the mixed species inoculum was then aliquoted in to the 5ml bijoux 
containing the autoclaved sutures and incubated as described above. 
 
7.2.4 Visualisation of biofilms 
7.2.4.1 Enumeration of bacteria in biofilm growth phase 
In order to distinguish between the two species when plated out on to agar, a selective agar 
Membrane Lauryl Sulphate Agar or MLSA was used. MLSA is usually used to detect coliform 
organisms and E. coli in water. The lactose-fermenting colonies appear yellow on the agar 
plates and can be used as a presumptive test for E.coli. A. baumannii appears as pink colonies 
on the agar surface as these organisms are non-lactose fermenting (NLF) organisms. To test 
for the presence of NLF after 24 hours of growth, individual pieces of suture were aseptically 
removed for the bijoux and placed in a new sterile 1.5ml Eppendorf containing 1ml of saline. 
The Eppendorf was then vortexed for 5 minutes to disrupt the biofilm from being attached to 
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the suture surface. Eight serial dilutions of this suspension were prepared and spread plated 
on to the MLSA plates and incubated at 37oC overnight. The morphology and colour of the 
colonies was recorded. 
In order to count of bacteria attached to individual suture pieces, the same procedure as 
above was performed, and the number of colonies was also recorded and the plates were 
read using a Scan® 500 plate reader (Interscience, France). 
 
7.2.4.2 Gram staining and Scanning Electron Microscope 
To assess the extent of biofilm growth on the suture, the suture was visualized using a high 
powered light microscope, individual suture pieces were aseptically removed from the bijou 
they had been incubated in using sterile forceps. Each piece was then rinsed twice using 
sterile PBS and gently placed on a clean glass slide. The ends of the suture were then carefully 
taped down to glass slides. The glass slides were then fixed and stained following Gram's 
staining protocol and visualised under a high powered light microscope at a total 
magnification of x100091. 
Suture pieces with A. baumannii attached to them were also visualised using scanning 
electron microscope. SEM is a powerful technique which enables the surface visualisation of 
samples at high magnifications. The electron microscope produces images by using a focused 
electron beam to generate a variety of signals that derive from electron-sample interactions, 
which reveal information about the sample including surface morphology. In this study the 
SEM was used to visualise both planktonic and biofilm cultures of A. baumannii.  
To visualise biofilm cultures, samples were grown on the suture as described in section 7.2.3. 
These samples were washed twice with PBS, and prepared for SEM examination by washing 
with 0.1M sodium cacodylate and fixing in 2.5% glutaraldehyde in 0.1M sodium cacodylate 
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for 30 minutes. Specimens were then wash twice in dH2O, dehydrated for 10 minutes at each 
stage of an ascending ethanol series (50% to 100%) and left to air dry92. Each sample was 
sputter coated in Carbon before visualization in the SEM. Samples were analysed under a FEI 
scanning electron microscope at a working distance of 10 mm (Quanta SEM, FEI™, USA).  
 
For the planktonic culture specimens, 1ml of an overnight culture was transferred to a new 
sterile Eppendorf and centrifuged at 11,000 xg for 3 minutes to form a pellet. The fixing 
procedure then followed the same procedure as for the biofilm samples. 
If at any point the pellet dissolved into the solutions, the mixture was centrifuged to form a 
pellet once more. 
 
7.2.5 Pathogenicity and treatment of biofilm attached to suture 
7.2.5.1 Checkerboard Assay 
As determined in Sections 4 and 5, the in vitro activity of colistin in combination with 
rifampicin or erythromycin was significantly better than that of the other broad spectrum 
agents in combination with colistin. Therefore the same combinations were used in the 
analysis of the in vitro activity of biofilm mode A. baumannii.  
Antibiotic synergy was determined in vitro using the well-established microdilution broth 
checkerboard assay technique [68]. The broad spectrum antibiotics (working concentrations 
ranging from 0.125 mg/L – 64 mg/L or 0.5 mg/L to 256 mg/L depending on initial MIC) were 
serially diluted across the ordinate whilst colistin (working concentrations 0.06 mg/L – 4 mg/L) 
was diluted along the abscissa. Plates were stored in a -20oC freezer then thoroughly 
defrosted before using. To assess the activity of bacteria and subsequent biofilm formation, 
100 µl of adjusted inoculum was aseptically added to flat bottomed 96 well tissue culture 
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plates. The peg systems were then carefully placed on top, each plate was sealed and 
incubated statically at 37oC for 24 hours. After 24 hours, the MBEC™ peg lids were then 
carefully and aseptically removed from the inoculated plate, rinse twice with PBS and added 
to the antibiotic checkerboard plates, which were then sealed and incubated at 37oC for 24 
hours.  
 
7.2.5.2 In vivo pathogenicity and therapeutics 
7.2.5.2.1 Single species  
Before the pathogenicity of the biofilm-associated infection could be assessed, it was 
essential to establish the pathogenicity of E. coli ATCC 25922 as a planktonic culture, in order 
to understand the behaviour of the bacteria and to be able to make a comparison. The 
pathogenicity of ATCC 25922 was established by following the same methodology described 
in section 3.2.3.  
To assess the pathogenicity of both single and mixed species biofilm-associated infection, 
25922 biofilms were grown on 3mm lengths of suture as previously described above in section 
7.2.3. After washing twice with PBS, each suture was carefully transferred to a sharpened 
sterile 20µl Gilson-type pipette tip (Sarstedt, Germany). The pipette tip was gently inserted in 
to the top left proleg of larvae and a fine needle was used to insert the biofilm suture into the 
body of the larvae. The groups of larvae were then incubated at 37oC for 96 hours alongside 
controls and survival rate was recorded every 24 hours. The degree of melanisation of each 
larva was also recorded. Larvae were determined as dead if they failed to respond to touch 
after 1 minute of stimulation. 
After the suture had been inserted, groups which were to receive either mono- or 
combination antibiotic treatment did so in the manner previously described in section 5.2. 
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7.3 RESULTS AND DISCUSSION 
7.3.1 Insertion trauma 
Immediately after stimulating the trauma associated with inserting the pipette tip into the 
proleg of individual initial observations of the different injection methods showed great deal 
of trauma was inflicted on the larval groups with a loss of hemolymph, however it was noted 
within minutes, a black scab like plug had formed around the entrance of the proleg (where 
the tip had entered) and the larvae continued to behave in their usual manner and so the 
survival rates of the two groups where then monitored over 96 hours to see if the trauma had any 
adverse effects on the survival rate of the tested group.   
Figure 7.1 shows the results of the survival analysis of the different trauma groups carried out 
over a 96 hour period. The graph shows after 96 hours, there was 100% survival rates in both the 
negative control and the group experiencing the trauma associated with the pipette injection. The 
Chi-squared statistical value for the difference between these groups was 4.131 with an 
associated P-value of less than 0.127 (95% confidence level) which is greater than the accepted 
level of statistical significance employed in this work is (P < 0.05) therefore it is possible to 
conclude that the trauma experienced in inserting the sterile suture via a sharpened pipette tip, 
does not cause a significant difference in survival rates compared to groups that receive the 
trauma of the tip alone or no trauma at all. 
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Figure 7.1: Kaplan Meier survival curve comparing the trauma experienced through inserting 
the suture in to individual larvae over a 96 hour test period. 
 
 
 
Table 7.1: The overall comparison for testing the equality of survival distributions for 
the different trauma groups. 
 
As mentioned briefly before, wound healing capabilities of G. mellonella larvae has been 
extensively studied by Rowley and Ratcliffe63. They found immediately after wounding both 
fat-body and hemolymph of the larvae were forced through the wound to form a plug. At the 
same time, the hemolymph coagulated forming vast networks of strand-like material 
attached to the hemocytes underlying the wound. After one to two hours this plug melanized 
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and the cells became highly necrotic. Six hours after wounding, there was a massive influx of 
hemocytes which eventually attached to the melanized layer over the wound to form a 
multicellular sheath. Twelve to twenty-four hours later, the epidermal cells underlying the 
broken cuticle detached and migrated across the wound to form a new intact layer. This 
intricate wound healing process, similar to that of the mammalian process, could explain why 
the trauma of the pipette tip was not found to significantly affect the survival rates of larvae. 
 
An important benefit to bear in mind with this model of biofilm injection is the ability to inject 
the suture in this manner is that the whole system becomes disposable. This minimises the 
risk of contamination and reducing the work load between injections as a cleaning step 
between each injection does not need to be employed. Therefore reducing time and work 
load during the administration of the suture in the Galleria model. 
 
7.3.2 Biofilm growth 
7.3.2.1 Enumeration of attached bacteria 
Initially, serial dilutions of vortexed suture in saline were plated on to MLSA plates in order to 
distinguish between species, Figure 7.1. The control plates clearly show the distinction 
between lactose-fermenting E. coli colonies (yellow colonies, figure 7.1a) and not lactose-
fermenting A. baumannii colonies (pink colonies, figure 7.1b). Figure 7.1c shows a plate which 
belongs to a suture that had a mixed species biofilm grown on it, both yellow and pink 
colonies grew on this plate helping to confirming the mixed growth of both E. coli and A. 
baumannii on the suture. 
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Figure 7.1: MLSA agar plates showing the distinctive differences between the two bacterial 
strain, E. coli ATCC 25922 and A. baumannii ATCC 19606. a) E. coli ATCC 25922 control plate 
b) A. baumannii ATCC 19606 control plate c) Mixed-species vortexed suture spread plate. 
 
As before, for the enumerate viable bacterial colonies, an assumption is made that each 
bacterial colony on immobilised on the agar plate arose from one living (viable) cell, therefore 
it is possible to determine the number of live bacteria defined as colony forming units per ml 
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of the original culture, with the general acceptance range for counting colony forming units 
being 30 to 300 colonies. Table 7.1 shows the results of the vortexed suture  
 
 
Dilution CFU/ml 
 
A. baumannii 1.37 x 106 
E.coli 4.29 x 106 
A.baumannii (mixed 
species suture) 
3.69 x 108 
E. coli (mixed species 
suture) 
6.95 x 108 
  
Table 7.2: Average CFU/ml values for A. baumannii ATCC 19606 and E. coli ATCC 25922 
grown as single and mixed species biofilms on surgical suture. 
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7.3.2.2 Gram Staining and SEM analysis 
The attachment of A. baumannii ATCC 19606 bacteria on the surgical suture pieces was 
investigated using Gram staining and SEM.  
                                                                   
 
 
 
 
 
Figure 7.2: Gram stain section of A. baumannii ATCC 19606 biofilm grown on surgical suture. 
Helicon focus software was used to overlay images to produce a clear focused in image. 
 
Gram stains distinguish between positive and negative bacteria by the dye that is retained 
within the bacterial cell walls. Gram positive bacteria hold on to the primary dye-iodine 
complex and stain violet. Gram negative bacteria are decolourised during the Gram stain 
process and take up the final dye stage, Safranin, and stain pink91, 93. The reasoning for the 
differences in staining is due to the properties of the bacteria’s cell wall. Gram negative 
Biofilm Matrix 
Suture 
Encapsulated 
bacteria 
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bacteria have thinner layered cell wall and also a larger number of lipids present in the walls 
compared to the cell walls of Gram-positive bacteria which may explain the differences in the 
Gram stain reactions93. As A. baumannii is a Gram-negative, the bacteria Gram stain should 
be pink. However A. baumannii is notoriously known as a difficult species to Gram stain, and 
therefore this can lead to misidentification. 
 
Encapsulated A. baumannii cells are clearly visible within the biofilm matrix in Figure 7.2 and 
the image shows the Gram negative coccobacillus shaped A. baumannii either attached 
directly to the suture, or within a translucent tent-like structure - the extracellular matrix 
formed from bacterial cell secreted extracellular polymeric substances.  
 
The appearance of biofilm formed by A. baumannii ATCC 19606 was also investigated using 
SEM. As a control, bacteria of the same isolate in planktonic growth phase were immobilised 
and analysed with the SEM. SEM analysis of the biofilm grown on suture samples show 
attached A. baumannii cells to the surface of the suture across all visible surfaces. Figure 
6.3(b) shows an SEM image at a higher magnification of bacteria adhered to the suture.  
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Figure 7.3 (a) Scanning electron image of biofilm growth phase A. baumannii ATCC 19606 
adhered to suture surface. (b) Scanning electron image of biofilm growth phase E.coli ATCC 
25922 adhered to the suture surface. (c) Scanning electron image of mixed species biofilm 
growth phase of A. baumannii ATCC 19606 and E.coli ATCC 25922 adhered to the suture 
surface. 
 
SEM analysis of the biofilm grown on suture samples show attached A. baumannii cells to the 
surface of the suture across all visible surfaces. Figure 7.3(b) shows an SEM image at a higher 
magnification of bacteria adhered to the suture.  
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Sparse EPS matrix surrounding bacterial cells of the single species biofilms, however the SEM 
image of the mixed species biofilms showed the EPS matrix clearly distinguishable on covering 
the micro-colonies. The combination of the two species demonstrate bountiful growth and 
colonisation with a thick extracellular matrix surrounding the cell aggregates vastly different 
biofilm formation, when compared to their sparely grown single species biofilms which had 
been grown for the same length of time. It would be possible to conclude that the 
combination of the two species has a symbiotic effect on the attachment and growth of mixed 
species biofilms. In terms of enumeration, this is reflected in the increase in viable cell counts 
for A. baumannii which increased from 1.37 x 106 to 3.69 x 108 CFU/ml.  
 
 
7.3.3 In vitro checkerboard assay 
Erythromycin alone displayed little activity against both single species of E. coli ATCC 25922 
and A. baumannii ATCC 19606 biofilm cultures, MIC values of 64 mg/L and 16 mg/L, 
respectively; whereas rifampicin when tested alone shows greater activity against both 
biofilm cultures, MIC values of 4 mg/L and 8 mg/L, respectively.  
Synergy between both erythromycin and rifampicin in combination with colistin, was 
observed in the biofilm culture when determined in the checkerboard MIC assays. The 
combination of rifampicin and colistin was highly active against the A. baumannii 19606 
biofilm infection with an FICI of 0.37 mg/L. The combination of erythromycin and colistin was 
also highly active against the biofilm cultures, also with an FICI of 0.37 mg/L. For E. coli ATCC 
25922 biofilm cultures, the combination of rifampicin with colistin was found to be far more 
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effective treatment with an FICI value of 0.137. Erythromycin in combination with colistin was 
also found to be synergist with FICI value of 0.37. Checkerboard assays for the mixed species 
biofilms were not performed. 
 
7.3.4 In vivo evaluation of treatment 
 
7.3.4.1  Biofilm kill kinetics 
Biofilms grown on sutures were quantified as 106 CFU/suture before injection and larval 
groups that have been infected in this way had a survival rate of (22.92% ± 3.61 Standard 
Deviation Percentage Points, [sdp]) after 96 hours. Figure 7.4 represents results from a single 
pathogenicity test.  
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Figure 7.4: Kaplan Meier survival curve comparing the pathogenicity of planktonic cultures 
at varying CFU/ml concentrations (103 – 106 CFU/Larva) and biofilm culture (106 CFU/suture) 
of Acinetobacter baumannii ATCC 19606 over a 96 hour test period. Graph represents 
results from a single test.   
 
As previously discussed, biofilm infections are generally considered to be more severe so why 
are these results showing the severity/pathogenicity of the biofilm infection to be less than 
that of its planktonic counterpart. After 24 hours, some of the larva showed signs of 
melanisation but their activity levels remained high. One explanation for this could be the 
induced immune response stimulated by the insertion of the pipette tip into the larva’s 
proleg. The intricate wound healing process, triggered after wounding, could explain the 
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presence of a high degree of melanisation which in this case did not always result in the larvals 
death as a greater number of larval survived infected via the suture model compared to the 
planktonic infection. The results could be explained by the larva’s immune response, triggered 
by the pipette tip, which had begun to not only effectively plug the wound trauma caused by 
the insertion of the suture but also the attached biofilm. 
For E. coli ATCC 25922, planktonic cultures were found highly pathogenic towards the G. 
mellonella larvae at levels greater than 105 CFU/Larva. 
Biofilm grown E. coli were found to be highly pathogenic towards G. mellonella larva, with 0% 
survival after 24 hours in all test groups. E. coli ATCC 25922 was found to be more pathogenic 
in both planktonic and biofilm grown deliberate infections compared to A. baumannii ATCC 
19606. 
Mixed species biofilms containing both A. baumannii ATCC 19606 and E. coli ATCC 25922 
species was also found to be highly pathogenic towards G. mellonella larva, with 0% survival 
after 24 hours in all test groups. The increase in pathogenicity in comparison to A. baumannii 
ATCC 19606 infections alone can be explained by the presence of E. coli ATCC 25922 bacteria 
in the mixed species biofilm. Data not shown. 
 
7.3.4.2 Efficacy of antimicrobial therapies in vivo against single and mixed-species biofilm infections 
 
Both planktonic evaluation and in vitro analysis showed the combination of either 
erythromycin or rifampicin with colistin to be significantly more active than either drug alone 
against deliberate lethal A. baumannii ATCC 19606 infections. This was also supported in vitro, 
with rifampicin combinations resulted in the highest percentage survival and therefore most 
active combination against A. baumannii biofilm-associated infection groups. 
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Culture % G.mellonella Survival after 96 hours 
No 
treatment 
Colistin Erythromycin Rifampicin Colistin-
Erythromycin 
Colistin-
Rifampicin 
E. coli 
biofilm 
0 91.67±3.61 - - - - 
A. 
baumannii 
biofilm 
33.33±7.22 33.33±7.22 27.08±9.55 41.67±9.55 47.92±9.55 72.92±3.61 
Mixed-
species 
biofilms 
0 77.08±13.01 - - - - 
 
Table 7.3: antimicrobial treatment efficacy against single and mixed species biofilm-
associated infections evaluated in a Galleria mellonella infection model 
 
 
Following treatment of A. baumannii biofilm-associated infections with colistin alone, the 
survival rate was 33.33% (± 7.22 sdp). Compared with treatment in combination with 
rifampicin (72.92%  ± 3.61 sdp) or erythromycin (47.92% ± 9.55 sdp) colistin combination 
therapy was significantly more active in treating ATCC 19606 lethal infections (t test, P = < 
0.01 and P = 0.05 respectively).  
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Figure 7.5: Kaplan Meier survival curves comparing the treatment of lethal biofilm A. 
baumannii ATCC 19606 infections with erythromycin and/or colistin alone and in 
combination. Survival was monitored every 24 hours over 96 hour period. Graph represents 
results from a single test. 
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Figure 7.6: Kaplan Meier survival curves comparing the treatment of lethal biofilm A. 
baumannii ATCC 19606 infections with rifampicin and/or colistin alone and in combination. 
Survival was monitored every 24 hours over 96 hour period. Graph represents results from a 
single test. 
 
 
Figure 7.5 and 7.6 shows a typical graphs of groups infected with biofilm grown cultures of 
ATCC 19606. It was unexpected that the pathogenicity of the biofilm-associated infection 
would be less lethal than that of the planktonic infection. However previously mentioned the 
larva’s own immune response could have been working synergistically with the colistin 
combination therapy in a much more complex way which requires further investigation. 
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In regards to E.coli pathogenicity, the overall survival of the control groups deliberately 
infected with pathogenic levels of either planktonic or biofilm-associated infections was 0% 
at 24 hours for all test groups see table 7.1 and figure 7.7. Following treatment with colistin 
alone, the survival rate increased to 83.33±3.61% and 91.67±3.61% respectively. Due to the 
high survival rate of the larva with the treatment of colistin alone, it was deemed unnecessary 
to further treat with the either of the other agents or colistin combination therapy, as in this 
study, colistin combinations are the subject of interest therefore if the agent alone sufficiently 
treats the infection, the combination therapy becomes redundant. Also by minimising the 
number and amount of antimicrobial agents used, this reduces the risk of the overuse of 
antibiotics when it is not necessary, which could result in increased chances of acquired 
antibiotic resistance towards colistin and the other broad spectrum antibiotics used in this 
study. 
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Figure 7.7: Kaplan Meier survival curve comparing the treatment of lethal planktonic and 
biofilm E. coli ATCC 25922 infections with either erythromycin, rifampicin and/or colistin 
alone and in combination. Survival was monitored every 24 hours over 96 hour period. 
Graph represents results from a single test. 
 
 
Figure 7.7 shows a typical Kaplan Meier survival curve comparing the treatment of lethal 
planktonic and biofilm E. coli ATCC 25922 infections with either erythromycin, rifampicin 
and/or colistin alone and in combination. The p-value was found to be significant (P<0.05), 
therefore it is possible to conclude that the chances of survival is dependent on whether the 
test group received treatment. 
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It is quite possible that the growth rate of the biofilm-associated infection greatly influences 
the survival rate of the larva. Where treatment has been applied immediately after the suture 
was injected in to the larva, it is possible that not enough time has passed for the infection to 
establish itself within the model. Further investigation in to the influence of time dependant 
administration would shed light on how the infection establishes itself in the G. mellonella 
model. 
Many studies have found a link between biofilm growth rates and susceptibility towards 
different antibiotics. DuGuid et al.94 found that Staphylococcus epidermidis biofilm growth 
rates strongly influenced susceptibility; from their study, they concluded the faster the rate 
of cell growth, the more rapid the rate of inactivation by ciprofloxacin. A review by Donlan 
and Costerton88 found other results supporting the idea that biofilm growth rates influence 
the susceptibility of the biofilm to antimicrobial agents with several different combinations of 
bacteria and antimicrobial agents. Therefore in the present study the rate at which the biofilm 
establishes itself within the G. mellonella model maybe influence the infections susceptibility 
to the agents tested.  
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7.3.4.2.1 Mixed species 
 
 
Figure 7.6: Kaplan Meier survival curve comparing single and mixed-species biofilms. 
Survival was monitored every 24 hours over 96 hour period. Graph represents results from a 
single test. 
 
Interestingly monotherapy treatment of colistin against the lethal mixed species biofilm 
associated infections resulted in average survival of 77.08±13.01, see table 7.3, which was 
found to be significantly higher than if the groups were to receive no treatment. Due to the 
high survival rate of the larva with the treatment of colistin alone, it was deemed unnecessary 
to further treat with the colistin combination therapy, therefore the other agents and 
combination therapies were not tested. This is a very interesting result as previous in vitro 
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analysis had not indicated towards this outcome. One possible explanation for this result 
could be that E. coli bacteria are controlling the pathogenicity of the mixed species biofilm 
through biofilm mechanism through quorum sensing (cell to cell communication). Quorum 
sensing as defined by Miller and Bassler95, is ‘the regulation of gene expression in response 
to fluctuations in cell-population density. Bacteria use quorum sensing communication to 
regulate a diverse array of physiological activities including, but not exclusive, 
bioluminescence, virulence and biofilm formation and dispersal. This cell to cell 
communication system occurs both within and between bacterial species, thereby 
coordinating group behaviour, critical for the survival and development of biofilms, including 
extracellular polymer production37, 95-97. 
In the present study, the cell signalling could be controlling the virulence of the mixed species 
biofilm, so that the virulence is infection is caused only by E. coli bacterial cells, which has 
previously been shown to be effectively treated with colistin alone. 
The explanation above does however raise future concerns about long term treatment of 
mixed species biofilm-associated infections due to the possible outcome of the ‘dormant’ A. 
baumannii cells becoming what is known as persister cells83. What is interesting about 
persister cells is that they are not just simply resistant to the antibiotics employed to treat the 
infection, rather there dormancy state allows them to recover the infection once the 
threshold of cells required to trigger quorum sensing has no longer been reached. In order 
words the dormant cells are able to recover the pathogenicity of the biofilm after treatment 
has removed the infective actively growing cells83. This raises long term concerns and 
therefore it would be interesting to see what would happen to the G. mellonella test groups 
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over a longer test period and see whether the infection would establish itself within the model 
later on in the study.  
 
7.4  SUMMARY OF RESULTS  
 
Although planktonically grown A baumannii produces an acute lethal effect at high numbers 
(105/106 CFU, Figure 4) the biofilm induced model in G. mellonella is probably a more realistic 
representation of infections that occur in nosocomial environments than direct inoculation 
with planktonic growth phase organisms. Also previously mentioned the larva’s own immune 
response could have been working synergistically with the colistin combination therapy in a 
much more complex way which requires further investigation. 
Treatment of colistin alone against the lethal mixed species biofilm associated infections 
resulted in 100% survival which could be as a result of E. coli bacteria are controlling the 
pathogenicity of the mixed species biofilm through mechanisms of quorum sensing (cell to 
cell communication). Comparing the single species results, E. coli biofilms were effectively 
treated with colistin alone, whereas there was a higher rate of survival in the groups treated 
with either colistin combination compared to treatment with colistin alone. It could be 
possible that E. coli cells are able to trigger the A. baumannii cells to become dormant 
resulting in the infection only displaying and exhibiting E. coli pathogenic traits, which was 
previously shown to be effectively treated with colistin alone however further analysis would 
be required to establish whether this is true. 
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8 GENERAL DISCUSSION 
The optimal treatment for A. baumannii, especially for those infections cause by multidrug 
resistant strains, still remains to be established. This study explored the use of combining old 
antibiotics, to which the bacteria are still susceptible to, with broad spectrum antibiotics to 
investigate if the agents together have a synergist effect on the treatment infections cause by 
MDR A. baumannii. 
Previous studies report that colistin when tested in vitro initially displays bactericidal activity 
against clinical strains of A.baumannii but this appears to be overcome after 24 hours15. The 
present study agrees that colistin does not possess sufficient bactericidal activity to overcome 
initial A. baumannii infections in the first phase of treatment. Since colistin demonstrates 
excellent synergy in vitro with the two tested BSA, and larval survival is significantly increased 
in the combination model of infection, suggesting there is sufficient bactericidal activity 
within the combinations that is able to overcome the infection. 
 
Cai et al.16 analysed antimicrobial strategies to avoid colistin resistance of A. baumannii 
comparing a number of patient studies evaluating combination therapies of colistin with a 
range of antibiotics, including rifampicin. Rifampicin/colistin combinations were shown in 
vitro, in vivo and in clinical reports to be promising therapeutic options against MDR A. 
baumannii infections. The model evaluated in the present study supports these finding and 
also provides evidence on the use of the rifampicin/colistin combination therapy against A. 
baumannii biofilm infections in a simple, cheap and ethically acceptable model. 
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Other macrolide antibiotics in combination with colistin have been shown previously to be 
synergists in vitro; Timurkaynak et al.79 found azithromycin in combination with colistin to be 
synergistic against three different A. baumannii isolates. In the present study, the macrolide 
erythromycin was found to both be synergist in vitro and significantly improved survival of 
the G. mellonella. 
Although planktonic grown A baumannii produces an acute lethal effect at high numbers 
(105/106 CFU, Figure 4) the biofilm induced model in G. mellonella is probably a more realistic 
representation of infections that occur in nosocomial environments than direct inoculation 
with planktonic grown organisms.  
 Interestingly treatment of synergistic combinations of colistin with either erythromycin or 
rifampicin against biofilm associated infections in G. mellonella is considerably more effective 
than with planktonic grown cells increased survival of those infected with the biofilm culture 
of 19606 show that the biofilm has induced the host immune system to a point where it is 
beginning to successful fight the infection. The biofilm grown organisms produced a less 
aggressive course of infection which may be due to modulation by the host defence peptides 
against a more localised infection within G. mellonella.   
 
8.1 CONCLUSIONS  
The work presented here provides positive in vivo model evidence of the efficacy of colistin 
as an effective synergist to treat serious infections in humans by A. baumannii. The 
combination of specific broad spectrum antibiotics shown to be synergistic with low 
concentrations of colistin may be useful drugs in patients. Effective combination therapy with 
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colistin could reduce the emergence of resistance and heteroresistance of A. baumannii to 
colistin. 
Treatment of colistin alone against the lethal mixed species biofilm associated infections 
resulted in 100% survival. This is a very interesting result as previous in vitro analysis had not 
indicated towards this outcome. One possible explanation for this result could be that E. coli 
bacteria are controlling the pathogenicity of the mixed species biofilm through biofilm 
mechanism through quorum sensing (cell to cell communication) which results in the A. 
baumannii cells becoming dormant therefore the infection only displays E. coli pathogenic 
traits, which has previously been shown to be effectively treated with colistin alone. 
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9 FURTHER WORK 
 
This work provides positive in vivo model evidence of the efficacy of colistin as an effective 
synergist to treat serious infections in humans by A. baumannii. The combination of specific 
broad spectrum antibiotics shown to be synergistic with low concentrations of colistin may 
be useful drugs in patients. Effective combination therapy with colistin could reduce the 
emergence of resistance and heteroresistance of A. baumannii to colistin. Therefore further 
work should be carried out to investigate minimum effective levels of the combination 
therapy against such prevalent nosocomial infections. Further work should also investigate 
the relationship between E. coli and A. baumannii species in regards to their pathogenicity 
traits within a mixed species biofilm. 
 
Highlighted within the literature was the lack of knowledge and understanding of the 
antimicrobial agents belonging to the Polymyxin family. Do to the drug being ‘abandoned’ 
during the 1950s, the agents have not undergone the same rigorous development procedures 
that other antimicrobial agents have. Therefore further work should be carried out 
investigating the pharmacokinetics and pharmacodynamics of this last resort antimicrobial 
family in order to maximise the activity of the drugs and also minimise the risk of antimicrobial 
resistance towards the drugs. 
Within the work carried out here, it was apparent that certain techniques had associated 
inherent errors within the method. In particular the stripping of the biofilm from the surgical 
suture in order to enumerate the number of total viable cells attached to the surface. Many 
assumptions are made when using this technique, such no cells were damaged during the 
vortexing procedure and therefore the number counted on the agar plates is the ‘true’ 
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number of viable cells. Also it is assumed that all cells are striped from the suture surface. 
One method which could be utilised to quantify the number of bacterial cells attached to the 
suture surface which possess high accuracy and precision is qPCR. By fluorescently tagging 
bacterial cells, and monitoring the increased signal and comparing to a calibration graph of 
known cell numbers it would be possible to accurately quantify the number of bacterial cells 
attached to the suture surface and this would prevent the inherent errors caused by the 
methods of quantification employed in this study. 
 
From the work carried out in this study, it suggested that that the growth rate of the biofilm-
associated infection greatly influences the survival rate of the larva. Where treatment has 
been applied immediately after the suture was injected in to the larva, it is possible that not 
enough time has passed for the infection to establish itself within the model. Further 
investigation would help establish the relationship between biofilm formation and growth 
within the Galleria mellonella model and is susceptibility towards certain antimicrobial 
agents. 
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11 APPENDIX 
11.1 SECTION 4 
11.1.1 ATCC 19606 Strain: Survival and mean tables 
 
 
 
 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 
71.665 4 .000 
Test of equality of survival distributions for the different levels of 
Group. 
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11.1.2 AYE Strain: Survival and mean tables 
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11.1.3 W Strain: Survival and mean tables 
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11.1.4 A14 Strain: Survival and mean tables 
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11.1.5 A17 Strain: Survival and mean tables 
 
 
125 
 
 
 
 
 
126 
 
11.1.6 A13 Strain: Survival and mean tables 
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11.1.7 A2 Strain: Survival and mean tables 
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11.1.8 Kill kinetics 
 
 Time (h) 
 4 6 8 10 12 24 
Repeat 1 1.56E+04 1.58E+06 7.62E+06 3.32E+09 5.30E+09 4.27E+04 
Repeat 2 1.37E+04 1.63E+06 5.02E+06 1.93E+09 2.02E+10 4.78E+04 
Repeat 3 1.40E+04 1900000 5.77E+06 1.91E+09 9.44E+09 7.55E+05 
Average 
CFU/ml 
1.44E+04 1.70E+06 6.14E+06 2.39E+09 1.16E+10 2.82E+05 
SD 1.02E+03 1.72E+05 1.34E+06 8.08E+08 7.69E+09 4.10E+05 
SE 5.90E+02 9.94E+04 7.73E+05 4.67E+08 4.44E+09 2.37E+05 
 
Analysis of kill kinetic test groups over 24 hour period 
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11.2 SECTION 5 
 
 
Table 4.1 Interpretation table of the checkerboard assay combining colistin with rifampicin. 
 
 
Table 4.2 Interpretation table of the checkerboard assay combining colistin with tetracycline. 
 
Clear 
Well 
 
Rifampicin (A) Colistin  (B) 
ƩFIC Interpretation Final Conc. 
(µg/ml) 
FIC  
Final Conc. 
(µg/ml) 
FIC 
A8 2 MIC of A 0 - - - 
B7 1 0.5 0.015 0.06 0.56 I 
B6 0.5 0.25 0.015 0.06 0.31 S 
B5 0.25 0.13 0.015 0.06 0.19 S 
B4 0.13 0.07 0.015 0.06 0.13 S 
C3 0.06 0.03 0.03 0.125 0.16 S 
D3 0.06 0.03 0.06 0.25 0.31 S 
E2 0.03 0.02 0.125 0.5 0.52 I 
F2 0.03 0.02 0.25 1 1.02 I 
F1 0 - 0.25 MIC of B - - 
 
Clear 
Well 
 
Tetracycline (A) Colistin  (B) 
ƩFIC Interpretation Final Conc. 
(µg/ml) 
FIC  
Final Conc. 
(µg/ml) 
FIC 
A7 1 MIC of A 0 - - - 
B7 1 1 0.015 0.06 1.06 I 
C7 1 1 0.03 0.13 1.13 I 
D6 0.5 0.5 0.06 0.25 0.75 I 
E5 0.25 0.25 0.125 0.5 0.75 I 
F4 0.125 0.125 0.25 1 1.125 I 
F3 0.06 0.06 0.25 1 1.06 I 
F2 0.03 0.03 0.25 1 1.03 I 
F1 0 - 0.25 MIC of B - - 
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Table 4.3 Interpretation table of the checkerboard assay combining colistin with kanamycin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clear 
Well 
 
Kanamycin (A) Colistin  (B) 
ƩFIC Interpretation Final Conc. 
(µg/ml) 
FIC  
Final Conc. 
(µg/ml) 
FIC 
A9 16 MIC of A 0 - - - 
B9 16 1 0.015 0.06 1.06 I 
C9 16 1 0.03 0.12 1.12 I 
D9 16 1 0.06 0.24 1.25 I 
E8 8 0.5 0.125 0.5 1.00 I 
E7 4 0.25 0.125 0.5 0.75 I 
F6 2 0.125 0.25 1 1.13 I 
F5 1 0.06 0.25 1 1.06 I 
F4 0.5 0.03 0.25 1 1.03 I 
F3 0.25 0.01 0.25 1 1.01 I 
F2 0.125 0.005 0.25 1 1.005 I 
F1 0 0 0.25 MIC of B - - 
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Table 4.4 Interpretation table of the checkerboard assay combining colistin with erythromycin. 
 
 
Table 4.5 Interpretation table of the checkerboard assay combining colistin with ciprofloxacin. 
 
 
Clear 
Well 
 
Erythromycin (A) Colistin  (B) 
ƩFIC Interpretation Final Conc. 
(µg/ml) 
FIC  
Final Conc. 
(µg/ml) 
FIC 
A10 32 MIC of A 0 - - - 
B9 16 0.5 0.015 0.06 0.56 I 
C9 16 0.5 0.03 0.12 0.62 I 
D8 8 0.25 0.06 0.2 0.49 S 
D7 4 0.125 0.06 0.2 0.37 S 
E6 2 0.06 0.125 0.5 0.56 I 
E5 1 0.03 0.125 0.5 0.53 I 
F4 0.5 0.01 0.25 1 1.01 I 
F3 0.25 0.007 0.25 1 1.007 I 
F2 0.125 0.003 0.25 1 1.003 I 
F1 0 - 0.25 MIC of B - - 
 
Clear 
Well 
 
Ciprofloxacin (A) Colistin  (B) 
ƩFIC Interpretation Final Conc. 
(µg/ml) 
FIC  
Final Conc. 
(µg/ml) 
FIC 
A9 16 MIC of A 0 - - - 
B9 16 1 0.015 0.06 1.06 I 
D8 8 0.5 0.06 0.24 0.74 I 
E7 4 0.25 0.125 0.5 0.75 I 
E6 2 0.125 0.125 0.5 0.625 I 
F5 1 0.06 0.25 1 1.06 I 
F4 0.5 0.03 0.25 1 1.03 I 
F3 0.25 0.01 0.25 1 1.01 I 
F2 0.125 0.005 0.25 1 1.005 I 
F1 0 - 0.25 MIC of B - - 
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Table 4.6 Interpretation table of the checkerboard assay combining colistin with gentamicin. 
 
 
Table 4.7 Interpretation table of the checkerboard assay combining colistin with chloramphenicol. 
 
 
Clear 
Well 
 
Gentamicin (A) Colistin  (B) 
ƩFIC Interpretation Final Conc. 
(µg/ml) 
FIC  
Final Conc. 
(µg/ml) 
FIC 
A10 32 MIC of A 0 - - - 
B9 32 1 0.015 0.06 1.06 I 
D8 16 0.5 0.06 0.24 0.74 I 
E7 8 0.25 0.125 0.5 0.75 I 
F5 2 0.063 0.25 1 1.06 I 
F4 1 0.031 0.25 1 1.03 I 
F3 0.5 0.016 0.25 1 1.02 I 
F2 0.25 0.008 0.25 1 1.005 I 
F1 0 - 0.25 MIC of B - - 
 
Clear 
Well 
 
Chloramphenicol (A) Colistin  (B) 
ƩFIC Interpretation Final Conc. 
(µg/ml) 
FIC  
Final Conc. 
(µg/ml) 
FIC 
A10 32 MIC of A 0 - - - 
B9 32 1 0.015 0.06 1.06 I 
D8 16 0.5 0.06 0.24 0.74 I 
E7 8 0.25 0.125 0.5 0.75 I 
E6 4 0.125 0.125 0.5 0.63 I 
F5 2 0.063 0.25 1 1.06 I 
F4 1 0.031 0.25 1 1.03 I 
F3 0.5 0.016 0.25 1 1.02 I 
F2 0.25 0.008 0.25 1 1.005 I 
F1 0 - 0.25 MIC of B - - 
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11.3 SECTION 6 
 
 Repeat   
Time 1 2 3  Average 
Standard 
Dev  
24 31.25 31.25 25 29.16667 3.608439 
48 31.25 18.75 18.75 22.91667 7.216878 
72 12.5 12.5 12.5 12.5 0 
96 18.75 12.5 12.5 14.58333 3.608439 
 
Treatment of biofilm grown ATCC 19606 with colistin 
 
 Repeat   
Time 1 2 3  Average 
Standard 
Dev  
24 31.25 31.25 25 29.16667 3.608439 
48 12.5 18.75 18.75 16.66667 3.608439 
72 12.5 6.25 6.25 8.333333 3.608439 
96 0 6.25 6.25 4.166667 3.608439 
 
Treatment of biofilm grown ATCC 19606 with erythromycin 
 
 
 Repeat   
Time 1 2 3  Average 
Standard 
Dev  
24 31.5 25 18.75 25.08333 6.375408 
48 12.5 25 18.75 18.75 6.25 
72 6.25 25 12.5 14.58333 9.547033 
96 6.25 18.75 12.5 12.5 6.25 
 
Treatment of biofilm grown ATCC 19606 with rifampicin 
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 Repeat   
Time 1 2 3  Average 
Standard 
Dev  
24 62.5 68.75 62.5 55.20833 3.608439 
48 50 43.75 43.75 41.66667 3.608439 
72 37.5 43.75 31.25 36.45833 6.25 
96 31.25 43.75 31.25 35.41667 7.216878 
 
Treatment of biofilm grown ATCC 19606 with colistin and erythromycin combination 
 
 
 Repeat   
Time 1 2 3  Average 
Standard 
Dev  
24 68.75 75 68.75 70.83333 3.608439 
48 62.5 62.5 68.75 64.58333 3.608439 
72 62.5 50 56.25 56.25 6.25 
96 43.75 37.5 43.75 41.66667 3.608439 
 
Treatment of biofilm grown ATCC 19606 with colistin and rifampicin combination 
 
 
F-Test Two-Sample for Variances   
   
  Variable 1 Variable 2 
Mean 12.5 41.66666667 
Variance 39.0625 13.02083333 
Observations 3 3 
df 2 2 
F 3  
P(F<=f) one-tail 0.25  
F Critical one-tail 19   
   
   
   
t-Test: Two-Sample Assuming Equal Variances  
   
  Variable 1 Variable 2 
Mean 12.5 41.66666667 
Variance 39.0625 13.02083333 
Observations 3 3 
Pooled Variance 26.04166667  
Hypothesized Mean Difference 0  
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df 4  
t Stat -7  
P(T<=t) one-tail 0.001096065  
t Critical one-tail 2.131846786  
P(T<=t) two-tail 0.00219213  
t Critical two-tail 2.776445105   
 
Planktonic ATCC19606 f-Test and T-Test comparison of the significance of treatment with rifampicin 
 
 
F-Test Two-Sample for Variances   
   
  Variable 1 Variable 2 
Mean 4.166666667 33.33333333 
Variance 13.02083333 13.02083333 
Observations 3 3 
df 2 2 
F 1  
P(F<=f) one-tail 0.5  
F Critical one-tail 0.052631579   
   
   
t-Test: Two-Sample Assuming Unequal Variances  
   
  Variable 1 Variable 2 
Mean 4.166666667 33.33333333 
Variance 13.02083333 13.02083333 
Observations 3 3 
Hypothesized Mean Difference 0  
df 4  
t Stat -9.89949494  
P(T<=t) one-tail 0.000292205  
t Critical one-tail 2.131846786  
P(T<=t) two-tail 0.000584411  
t Critical two-tail 2.776445105   
 
Planktonic ATCC19606 f-Test and T-Test comparison of the significance of treatment with 
erythromycin 
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11.4 SECTION 7 
 
11.4.1 Treatment of biofilm grown A. baumannii ATCC 19606 
 
 Repeat   
Time 1 2 3  Average 
Standard 
Dev  
24 68.75 62.5 68.75 66.66667 3.608439 
48 50 43.75 50 47.91667 3.608439 
72 43.75 37.5 43.75 41.66667 3.608439 
96 37.5 25 37.5 33.33333 7.216878 
 
Colistin 
 
 Repeat   
Time 1 2 3  Average 
Standard 
Dev  
24 37.5 37.5 43.75 39.58333 3.608439 
48 25 25 43.75 31.25 10.82532 
72 25 25 37.5 29.16667 7.216878 
96 18.75 25 37.5 27.08333 9.547033 
 
Erythromycin 
 
 
 
 
 
 
 Repeat   
Time 1 2 3  Average 
Standard 
Dev  
24 75 68.75 68.75 70.83333 3.608439 
48 68.75 68.75 68.75 68.75 0 
72 68.75 56.25 56.25 60.41667 7.216878 
96 50 43.75 31.25 41.66667 9.547033 
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Rifampicin 
 
 
 
 
 Repeat   
Time 1 2 3  Average Standard Dev  
24 68.75 75 50 64.58333 13.01041 
48 68.75 62.5 50 60.41667 9.547033 
72 50 56.25 43.75 50 6.25 
96 50 56.25 37.5 47.91667 9.547033 
 
Colistin and Erythromycin 
 
 
 
F-Test Two-Sample for Variances   
   
  Variable 1 Variable 2 
Mean 33.33333333 72.91666667 
Variance 52.08333333 13.02083333 
Observations 3 3 
df 2 2 
F 4  
P(F<=f) one-tail 0.2  
F Critical one-tail 19   
   
   
   
t-Test: Two-Sample Assuming Equal Variances  
   
  Variable 1 Variable 2 
Mean 33.33333333 72.91666667 
Variance 52.08333333 13.02083333 
Observations 3 3 
Pooled Variance 32.55208333  
Hypothesized Mean Difference 0  
df 4  
t Stat -8.49705831  
P(T<=t) one-tail 0.000525985  
t Critical one-tail 2.131846786  
P(T<=t) two-tail 0.00105197  
t Critical two-tail 2.776445105   
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Biofilm ATCC 19606 f-Test and T-Test comparison of the significance of treatment with rifampicin 
 
 
 
F-Test Two-Sample for Variances   
   
  Variable 1 Variable 2 
Mean 47.91666667 33.33333333 
Variance 91.14583333 52.08333333 
Observations 3 3 
df 2 2 
F 1.75  
P(F<=f) one-tail 0.363636364  
F Critical one-tail 19   
   
   
t-Test: Two-Sample Assuming Equal Variances  
   
  Variable 1 Variable 2 
Mean 47.91666667 33.33333333 
Variance 91.14583333 52.08333333 
Observations 3 3 
Pooled Variance 71.61458333  
Hypothesized Mean Difference 0  
df 4  
t Stat 2.110579412  
P(T<=t) one-tail 0.051211767  
t Critical one-tail 2.131846786  
P(T<=t) two-tail 0.102423533  
t Critical two-tail 2.776445105   
 
 
Biofilm ATCC 19606 f-Test and T-Test comparison of the significance of treatment with erythromycin 
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11.4.2 Planktonic and biofilm grown E.coli treatment 
 
 
1 
141 
 
 
142 
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11.4.3 Mixed biofilm treatment 
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11.4.4 Total Viable counts 
 
Raw data for total viable counts for A. baumannii ATCC 19606 cultured in a single species biofilm 
on to surgical suture. 
 
 
 
Raw data for total viable counts for A. baumannii ATCC 19606 cultured in a mixed species biofilm 
on to surgical suture. 
 
N° Count Dilution CFU/mL 
CFU 
Prorata 
Area 
(%) 
mean CFU Ø 
(mm) 
min CFU Ø 
(mm) 
max CFU Ø 
(mm) Date 
1 237 
1.00E-
03 2.87E+06 287 83 0.95 0.63 1.56 05/02/2014 
2 381 
1.00E-
02 4.06E+05 406 94 1.06 0.55 2.09 05/02/2014 
3 79 
1.00E-
03 8.41E+05 84 94 1.01 0.63 1.65 05/02/2014 
  Average 1.37E+06       
          
          
N° Count Dilution CFU/mL 
CFU 
Prorata Area (%) 
mean 
CFU Ø 
(mm) 
min CFU 
Ø (mm) 
max 
CFU Ø 
(mm) Date 
A.baumannii 
1 176 
1.00E-
07 4.84E+08 3 3.63E+08 0 0 5 12/02/2014 
A.baumannii 
2 294 
1.00E-
06 3.39E+08 26 3.15E+08 2 24200000 34 12/02/2014 
A.baumannii 
3 235 
1.00E-
05 2.85E+08 228 2.76E+08 0 0 285 12/02/2014 
  Average 3.69E+08       
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Raw data for total viable counts for E. coli ATCC 25922 cultured in a mixed species biofilm on to 
surgical suture. 
 
 
 
 
 
Raw data for total viable counts for E. coli ATCC 25922 cultured in a single species biofilm on to 
surgical suture. 
 
 
 
 
 
 
 
 
 
 
Sample 
N° Count Dilution CFU/mL 
Class 
1 
CFU 
Prorata 
Area 
(%) 
mean 
CFU Ø 
(mm) 
min 
CFU Ø 
(mm) 
max 
CFU Ø 
(mm) Date 
E.coli 1 9 
1.00E-
07 9.17E+08 9 9 98 3.6 0.63 6.25 23/04/2014 
E.coli 2 84 
1.00E-
06 9.44E+08 84 94 89 2.03 0.59 4.4 23/04/2014 
E.coli 3 199 
1.00E-
05 2.24E+08 197 224 89 1.71 0.59 4.07 23/04/2014 
  Average 6.95E+08        
Sample 
N° Count Dilution CFU/mL 
CFU 
Prorata 
Area 
(%) 
mean CFU 
Ø (mm) 
min CFU 
Ø (mm) 
max CFU 
Ø (mm) Date 
E.coli G 
2 227 
1.00E-
06 2.72E+09 272 83 2.43 0.78 5.75 21/03/2014 
E.coli G 
3 43 
1.00E-
07 5.85E+09 59 73 3.69 1.09 6.87 21/03/2014 
E.coli G 
4 8 
1.00E-
08 1.16E+10 12 69 3.98 3.15 6.23 21/03/2014 
  Average 4.29E+09       
